NanoViricides (NNVC) 10-Q 14 Feb 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 14, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'NANOVIRICIDES, INC.	'
Entity Central Index Key	'0001379006	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Non-accelerated Filer	'
Trading Symbol	'NNVC	'
Entity Common Stock, Shares Outstanding	'	53,957,000
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
CURRENT ASSETS:	'	'
Cash and cash equivalents	$16,948,832	$13,923,245
Prepaid expenses	806,391	598,380
Total Current Assets	17,755,223	14,521,625
PROPERTY AND EQUIPMENT	'	'
Property and equipment	3,859,244	1,505,648
Accumulated depreciation	-1,138,437	-1,036,752
Property and equipment, net	2,720,807	468,896
TRADEMARK	'	'
Trademark	458,954	458,954
Accumulated amortization	-46,308	-41,921
Trademark, net	412,646	417,033
SECURITY DEPOSIT	2,000,000	1,000,000
Total Assets	22,888,676	16,407,554
CURRENT LIABILITIES:	'	'
Accounts payable	244,280	263,258
Accounts payable - related parties	886,592	710,567
Accrued expenses	224,890	204,359
Total Current Liabilities	1,355,762	1,178,184
LONG TERM LIABILITIES:	'	'
Debentures payable	3,744,327	3,468,073
Derivative liability	7,577,919	3,751,645
Total Long Term Liabilities	11,322,246	7,219,718
Total Liabilities	12,678,008	8,397,902
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $0.001 par value; 85,714,286 shares authorized; 50,042,132 and 47,026,173 shares issued and outstanding, respectively	50,042	47,026
Additional paid-in capital	56,422,575	46,259,420
Deficit accumulated during the development stage	-46,264,946	-38,299,784
Total Stockholders' Equity	10,210,668	8,009,652
Total Liabilities and Stockholders' Equity	22,888,676	16,407,554
Series A Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	2,997	2,990
Series B Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	$0	$0

Balance_Sheets_Parenthetical

Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2013
			Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	'	'	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	'	'	4,000,000	4,000,000	0	0	0	0
Preferred stock, shares issued	'	'	2,996,612	2,990,000	0	0	0	0
Preferred stock, shares outstanding	'	'	2,996,612	2,990,000	0	0	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00	'	'	'	'	'	'
Common stock, shares authorized	85,714,286	85,714,286	'	'	'	'	'	'
Common stock, shares issued	50,042,132	47,026,173	'	'	'	'	'	'
Common stock, shares, outstanding	50,042,132	47,026,173	'	'	'	'	'	'

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		6 Months Ended		104 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING EXPENSES	'	'	'	'	'
Research and development	$1,130,478	$710,197	$2,304,699	$1,920,015	$25,108,759
Refund credit research and development costs	0	0	0	0	-420,842
General and administrative	620,934	533,407	1,335,495	917,229	14,350,343
Total operating expenses	1,751,412	1,243,604	3,640,194	2,837,244	39,038,260
LOSS FROM OPERATIONS	-1,751,412	-1,243,604	-3,640,194	-2,837,244	-39,038,260
OTHER INCOME (EXPENSE):	'	'	'	'	'
Interest income	14,501	15,495	24,061	51,453	291,759
Interest expense	-125,514	'	-246,500	'	-423,538
Discount on convertible debentures	-140,773	0	-276,254	0	-1,264,687
Beneficial conversion feature of convertible debentures	0	0	0	0	-713,079
Change in fair market value of derivatives	310,816	19,724	-3,826,275	-226,549	-5,117,141
Other income (expense), net	59,030	35,219	-4,324,968	-175,096	-7,226,686
LOSS BEFORE INCOME TAX PROVISION	-1,692,382	-1,208,385	-7,965,162	-3,012,340	-46,264,946
INCOME TAX PROVISION	0	0	0	0	0
NET LOSS	($1,692,382)	($1,208,385)	($7,965,162)	($3,012,340)	($46,264,946)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in dollars per share)	($0.03)	($0.03)	($0.16)	$0.07	'
Weighted average common shares outstanding - basic and diluted (in shares)	50,031,363	45,098,572	48,851,696	44,946,015	'

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Received [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]
Balance at May. 11, 2005	$0	$0	$0	$0	$0	'	'	'
Balance (in shares) at May. 11, 2005	'	0	'	'	'	'	'	'
Common shares issued May 12, 2005 (Inception)	0	6	14	-20	'	'	'	'
Common shares issued May 12, 2005 (Inception) (in shares)	'	5,714	'	'	'	'	'	'
Share exchange with Edot-com.com Inc., June 1, 2005	0	-6	-14	20	'	'	'	'
Share exchange with Edot-com.com Inc., June 1, 2005 (in shares)	'	-5,714	'	'	'	'	'	'
Common shares exchanged in reverse acquisition of Edot-com.com Inc., June 1, 2005	0	22,857	-22,837	-20	'	'	'	'
Common shares exchanged in reverse acquisition of Edot-com.com Inc., June 1, 2005 (in shares)	'	22,857,143	'	'	'	'	'	'
Common shares outstanding Edot-com.com Inc., June 1, 2005	0	5,714	-5,714	'	'	'	'	'
Common shares outstanding Edot-com.com Inc., June 1, 2005 (in shares)	'	5,714,286	'	'	'	'	'	'
Options granted in connection with reverse acquisition	0	'	0	'	'	'	'	'
Net loss	-66,005	'	0	'	-66,005	'	'	'
Balance at Jun. 30, 2005	-66,005	28,571	-28,551	-20	-66,005	0	0	0
Balance (in shares) at Jun. 30, 2005	'	28,571,429	'	'	'	0	0	0
Discount related to beneficial conversion feature of Convertible debentures, July 13, 2005	5,277	'	5,277	'	'	'	'	'
Legal expenses related private placement of common stock, July 31, 2006	-2,175	'	-2,175	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, July 31, 2005	5,302	'	5,302	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For August	4,094	'	4,094	'	'	'	'	'
Options issued to officers, September 23, 2005	87,318	'	87,318	'	'	'	'	'
Common shares issued for consulting services, September	186,300	657	185,643	'	'	'	'	'
Common shares issued for consulting services, September (In shares)	'	657,143	'	'	'	'	'	'
Common shares issued for interest on debentures, September 30, 2005	4,315	14	4,301	'	'	'	'	'
Common shares issued for interest on debentures, September 30, 2005 (in shares)	'	13,765	'	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, October 28, 2005	166,666	'	166,666	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, November 9, 2005	166,667	'	166,667	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, November 10, 2005	45,000	'	45,000	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, November 11, 2005	275,000	'	275,000	'	'	'	'	'
Discount related to beneficial conversion feature of Convertible debentures, November 15, 2005	49,167	'	49,167	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 28, 2005	170,000	97	169,903	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 28, 2005 (in shares)	'	97,143	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 29, 2005	150,000	86	149,914	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 29, 2005 (in shares)	'	85,715	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 30, 2005	75,000	43	74,957	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, November 30, 2005 (in shares)	'	42,857	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	25,876	'	25,876	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 2, 2005	50,000	29	49,971	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 2, 2005 (in shares)	'	28,571	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 6, 2005	425,000	243	424,757	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 6, 2005 (in shares)	'	242,857	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	49,067	'	49,067	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	51,048	'	51,048	'	'	'	'	'
Common shares issued for legal services valued at $.95 per share, December 6, 2005	19,000	6	18,994	'	'	'	'	'
Common shares issued for legal services valued at $.95 per share, December 6, 2005 (in shares)	'	5,714	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 12, 2005	375,000	214	374,786	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 12, 2005 (in shares)	'	214,286	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 13, 2005	25,000	14	24,986	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 13, 2005 (in shares)	'	14,286	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 14, 2005	25,000	14	24,986	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 14, 2005 (in shares)	'	14,285	'	'	'	'	'	'
Common shares issued in connection with debenture offering, December 15, 2005	49,000	14	48,986	'	'	'	'	'
Common shares issued in connection with debenture offering, December 15, 2005 (in shares)	'	14,286	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 20, 2005	25,000	14	24,986	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 20, 2005 (in shares)	'	14,285	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 29, 2005	25,000	14	24,986	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 29, 2005 (in shares)	'	14,286	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 30, 2005.	25,000	14	24,986	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, December 30, 2005. (in shares)	'	14,285	'	'	'	'	'	'
Common shares issued for interest on debentures, December 31, 2005	17,340	6	17,334	'	'	'	'	'
Common shares issued for interest on debentures, December 31, 2005 (in shares)	'	5,565	'	'	'	'	'	'
Common shares issued for consulting services valued per share, January	5,001	1	5,000	'	'	'	'	'
Common shares issued for consulting services valued per share, January (in shares)	'	978	'	'	'	'	'	'
Common shares issued for interest on debentures, March 31, 2005	22,192	2	22,190	'	'	'	'	'
Common shares issued for interest on debentures, March 31, 2005 (in shares)	'	2,263	'	'	'	'	'	'
Options exercised, May 31, 2006	90,000	515	89,485	'	'	'	'	'
Options exercised, May 31, 2006 (in shares)	'	514,286	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, June 15, 2006	1,875,000	536	1,874,464	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, June 15, 2006 (in shares)	'	535,714	'	'	'	'	'	'
Common shares issued for interest on debentures, June 30, 2006	22,438	4	22,434	'	'	'	'	'
Common shares issued for interest on debentures, June 30, 2006 (in shares)	'	4,122	'	'	'	'	'	'
Net loss	-3,284,432	'	'	'	-3,284,432	'	'	'
Balance at Jun. 30, 2006	1,238,456	31,108	4,557,805	-20	-3,350,437	0	0	0
Balance (in shares) at Jun. 30, 2006	'	31,108,121	'	'	'	0	0	0
Common shares issued for consulting services valued per share, January	164,160	62	164,098	'	'	'	'	'
Common shares issued for consulting services valued per share, January (in shares)	'	61,714	'	'	'	'	'	'
Common shares issued for interest on debentures, July 31, 2006	7,644	2	7,642	'	'	'	'	'
Common shares issued for interest on debentures, July 31, 2006 (in shares)	'	1,641	'	'	'	'	'	'
Common shares issued for conversion of convertible debentures, July 31, 2006	1,000,000	952	999,048	'	'	'	'	'
Common shares issued for conversion of convertible debentures, July 31, 2006 (in shares)	'	952,381	'	'	'	'	'	'
Exercise of stock warrants, July 31, 2006	50,000	57	49,943	'	'	'	'	'
Exercise of stock warrants, July 31, 2006 (in shares)	'	57,143	'	'	'	'	'	'
Options issued to Scientific Advisory Board, August 15, 2006	30,184	'	30,184	'	'	'	'	'
Options issued to Scientific Advisory Board, November 15, 2006	25,888	'	25,888	'	'	'	'	'
Options issued to Scientific Advisory Board, February 15, 2007	32,668	'	32,668	'	'	'	'	'
Options issued to Scientific Advisory Board, May 15, 2007	25,664	'	25,664	'	'	'	'	'
Common shares issued for consulting services valued per share, June	775	0	775	'	'	'	'	'
Common shares issued for consulting services value per share, June (in shares)	'	215	'	'	'	'	'	'
Common shares issued for consulting services valued at $1.15 per share, June 20, 2007	115,000	29	114,971	'	'	'	'	'
Common shares issued for consulting services valued at $1.15 per share, June 20, 2007 (in shares)	'	28,572	'	'	'	'	'	'
Common shares issued upon warrants conversion, June 20, 2007	620,000	266	619,734	'	'	'	'	'
Common shares issued upon warrants conversion, June 20, 2007 (In shares)	'	265,714	'	'	'	'	'	'
Common shares issued upon warrants conversion, June 25, 2007	50,000	21	49,979	'	'	'	'	'
Common shares issued upon warrants conversion, June 25, 2007 (in shares)	'	21,429	'	'	'	'	'	'
Common shares issued upon warrants conversion, June 30, 2007	200,000	86	199,914	'	'	'	'	'
Common shares issued upon warrants conversion, June 30, 2007 (in shares)	'	85,714	'	'	'	'	'	'
Common shares issued for consulting services valued at $1.06 per share, June 30, 2007	31,800	9	31,791	'	'	'	'	'
Common shares issued for consulting services valued at $1.06 per share, June 30, 2007 (in shares)	'	8,540	'	'	'	'	'	'
Officers' compensation expense	27,062	'	27,062	'	'	'	'	'
Net loss	-3,118,963	'	0	'	-3,118,963	'	'	'
Balance at Jun. 30, 2007	500,338	32,592	6,937,166	-20	-6,469,400	0	0	0
Balance (in shares) at Jun. 30, 2007	'	32,591,184	'	'	'	0	0	0
Warrants issued to Scientific Advisory Board, For August	14,800	'	14,800	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	7,200	'	7,200	'	'	'	'	'
Common shares issued for consulting and legal services For December	26,900	16	26,884	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	16,329	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	8,500	'	8,500	'	'	'	'	'
Common shares issued for employee stock compensation, March	27,900	18	27,882	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	17,585	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	32,253	'	32,253	'	'	'	'	'
Common shares issued for consulting services valued per share, June	27,900	9	27,891	'	'	'	'	'
Common shares issued for consulting services value per share, June (in shares)	'	8,526	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 21, 2007	750,000	429	749,571	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 21, 2007 (in shares)	'	428,571	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, October 16, 2007	1,625,000	929	1,624,071	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, October 16, 2007 (in shares)	'	928,571	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, October 16, 2007	125,000	71	124,929	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, October 16, 2007 (in shares)	'	71,428	'	'	'	'	'	'
Collection of stock subscription receivable	20	'	0	20	'	'	'	'
Options issued to officers, January 1, 2008	7,044	'	7,044	'	'	'	'	'
Common shares issued for consulting services valued at $.39 per share, April , 2008	10,821	8	10,813	'	'	'	'	'
Common shares issued for consulting services valued at $.39 per share, April , 2008 (in shares)	'	7,929	'	'	'	'	'	'
Common shares issued for legal services valued per share, September	18,400	7	18,393	'	'	'	'	'
Common shares issued for legal services valued per share, September (in shares)	'	7,213	'	'	'	'	'	'
Net loss	-2,738,337	'	0	'	-2,738,337	'	'	'
Balance at Jun. 30, 2008	443,739	34,079	9,617,397	0	-9,207,737	0	0	0
Balance (in shares) at Jun. 30, 2008	'	34,077,336	'	'	'	0	0	0
Warrants issued to Scientific Advisory Board, For August	47,500	0	47,500	'	'	'	'	'
Common shares issued for consulting services, September	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, September (In shares)	'	1,600	'	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	2,012	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	30,500	0	30,500	'	'	'	'	'
Common shares issued for consulting and legal services For November	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	2,132	'	'	'	'	'	'
Common shares issued for consulting and legal services For December	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	1,721	'	'	'	'	'	'
Common shares issued for consulting and legal services For January	4,999	2	4,997	'	'	'	'	'
Common shares issued for consulting and legal services For January (in shares)	'	2,132	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	29,000	0	29,000	'	'	'	'	'
Common shares issued for consulting and legal services February	4,999	2	4,997	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	2,012	'	'	'	'	'	'
Common shares issued for consulting and legal services, For March	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	1,831	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	2,059	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	30,600	0	30,600	'	'	'	'	'
Common shares issued for consulting and legal services, May	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	2,171	'	'	'	'	'	'
Common shares issued for consulting and legal services, June	5,000	3	4,997	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	2,560	'	'	'	'	'	'
Common shares issued for consulting and legal services July	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	1,171	'	'	'	'	'	'
Common shares issued for consulting services, July	2,800	1	2,799	'	'	'	'	'
Common shares issued for consulting services, July (in shares)	'	656	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, August 22, 2008	3,136,000	896	3,135,104	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, August 22, 2008 (in shares)	'	896,000	'	'	'	'	'	'
Common shares issued to settle account payable	150,000	43	149,957	'	'	'	'	'
Common shares issued to settle account payable (in shares)	'	42,857	'	'	'	'	'	'
Payment of Finder's Fee	-14,696	0	-14,696	'	'	'	'	'
Common shares issued in connection with Warrant Conversion, August 22, 2008	106,250	36	106,214	'	'	'	'	'
Common shares issued in connection with Warrant Conversion, August 22, 2008 (in shares)	'	35,714	'	'	'	'	'	'
Common shares issued forlegal services valued at $1.24per share, August 31, 2008	5,000	1	4,999	'	'	'	'	'
Common shares issued for legal services valued at $1.24per share, August 31, 2008 (in shares)	'	1,152	'	'	'	'	'	'
Common shares issued for consulting services, August	2,800	1	2,799	'	'	'	'	'
Common shares issued for consulting services, August (in shares)	'	645	'	'	'	'	'	'
Common shares issued for legal services valued per share, September	5,000	1	4,999	'	'	'	'	'
Common shares issued for legal services valued per share, September (in shares)	'	1,429	'	'	'	'	'	'
Common shares issued for consulting services, October	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, October (in shares)	'	2,254	'	'	'	'	'	'
Common shares issued for consulting services, November	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, November (in shares)	'	2,388	'	'	'	'	'	'
Common shares issued for consulting services, December	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, December (in shares)	'	1,928	'	'	'	'	'	'
Common shares issued for legal services valued at $ .60 per share, January 20, 2009	5,000	2	4,998	'	'	'	'	'
Common shares issued for legal services valued at $ .60 per share, January 20, 2009 (in shares)	'	2,381	'	'	'	'	'	'
Common shares issued for consulting services valued at $.78 per share, January 31, 2009	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services valued at $.78 per share, January 31, 2009 (in shares)	'	2,388	'	'	'	'	'	'
Common shares issued for consulting services valued at $ .70 per share, February 1, 2009	35,000	14	34,986	'	'	'	'	'
Common shares issued for consulting services valued at $ .70 per share, February 1, 2009 (in shares)	'	14,286	'	'	'	'	'	'
Common shares issued for consulting services, February	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, February (in shares)	'	2,254	'	'	'	'	'	'
Common shares issued for consulting services, March	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, March (in shares)	'	2,051	'	'	'	'	'	'
Common shares issued to acquire equipment valued at $0.79 per share	137,500	49	137,451	'	'	'	'	'
Common shares issued to acquire equipment valued at $0.79 per share (in shares)	'	49,286	'	'	'	'	'	'
Common shares issued for consulting services valued at $.69 per share, April 30, 2009	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services valued at $.69 per share, April 30, 2009 (in shares)	'	2,305	'	'	'	'	'	'
Common shares issued for consulting services valued at $.66 per share, May 31, 2009	5,598	2	5,596	'	'	'	'	'
Common shares issued for consulting services valued at $.66 per share, May 31, 2009 (in shares)	'	2,432	'	'	'	'	'	'
Common shares issued for consulting services valued at $ .61 per share, June 30, 2009	15,000	7	14,993	'	'	'	'	'
Common shares issued for consulting services valued at $ .61 per share, June 30, 2009 (in shares)	'	7,063	'	'	'	'	'	'
Shares issued for consulting services valued at $.56 per share, June 30, 2009	5,600	3	5,597	'	'	'	'	'
Shares issued for consulting services valued at $.56 per share, June 30, 2009 (in shares)	'	2,868	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, June 30, 2009	75,000	43	74,957	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, June 30, 2009 (in shares)	'	42,857	'	'	'	'	'	'
Common shares and warrants issued in connection with warrant conversion, June 30, 2009	925,350	586	1,024,764	-100,000	'	'	'	'
Common shares and warrants issued in connection with warrant conversion, June 30, 2009 (in shares)	'	585,914	'	'	'	'	'	'
Net loss	-2,787,798	'	0	'	-2,787,798	'	'	'
Balance at Jun. 30, 2009	2,485,541	35,800	14,545,276	-100,000	-11,995,535	0	0	0
Balance (in shares) at Jun. 30, 2009	'	35,799,845	'	'	'	0	0	'
Warrants issued to Scientific Advisory Board, For August	41,400	0	41,400	'	'	'	'	'
Common shares issued for consulting and legal services, August	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	1,861	'	'	'	'	'	'
Common shares issued for consulting services, September	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, September (In shares)	'	1,798	'	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	1,605	'	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares	-1,787,379	0	-1,787,379	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	1,960	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	39,600	0	39,600	'	'	'	'	'
Common shares issued for consulting and legal services For November	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	1,661	'	'	'	'	'	'
Common shares issued for consulting and legal services For December	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	1,687	'	'	'	'	'	'
Common shares issued for consulting and legal services For January	5,000	1	4,999	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation March One	513,823	0	513,752	'	'	71	'	'
Series A Preferred Shares issued for employee stock compensation March One (in shares)	'	0	'	'	'	71,429	'	'
Common shares issued for consulting and legal services For January (in shares)	'	1,370	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	40,200	0	40,200	'	'	'	'	'
Common shares issued for employee stock compensation for March One	156,250	36	156,214	'	'	'	'	'
Common shares issued for employee stock compensation for March One (in shares)	'	35,714	'	'	'	'	'	'
Common shares issued for employee stock compensation, March	156,250	36	156,214	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	35,714	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March	513,823	0	513,752	'	'	71	'	'
Series A Preferred Shares issued for employee stock compensation, March (in shares)	'	0	'	'	'	71,429	'	'
Series A Preferred Shares issued for employee stock compensation, March Two	192,684	0	192,656	'	'	28	'	'
Series A Preferred Shares issued for employee stock compensation, March Two (in shares)	'	0	'	'	'	26,786	'	'
Common shares issued for consulting and legal services, For March	1,250	0	1,250	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	286	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	685	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One	319	91	228	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One (in shares)	'	91,237	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	82,800	0	82,800	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One	16,877	3	16,874	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One (in shares)	'	2,943	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One	-60	0	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One (in shares)	'	0	'	'	'	'	-17,143	'
Dividend paid to Seaside 88, LP, May One	-16,877	0	-16,877	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May One	128,053	0	128,053	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Two	398	113	285	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Two (in shares)	'	113,768	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Two	-60	0	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Two (in shares)	'	0	'	'	'	'	-17,143	'
Derivative liability - retirement of Series B Preferred Shares, May Two	151,842	0	151,842	'	'	'	'	'
Dividend paid to Seaside 88, LP, June One	-14,575	0	-14,575	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, June One	14,575	3	14,572	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, June One (in shares)	'	2,962	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June One	427	122	305	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June One (in shares)	'	121,920	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June One	-60	0	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June One (in shares)	'	0	'	'	'	'	-17,143	'
Derivative liability - retirement of Series B Preferred Shares, June One	149,354	0	149,354	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June Two	378	108	270	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June Two (in shares)	'	107,973	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June Two	-60	0	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June Two (in shares)	'	0	'	'	'	'	-17,143	'
Common shares issued as Dividend to Seaside 88, LP June Two	12,274	2	12,272	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP June Two (in shares)	'	2,209	'	'	'	'	'	'
Derivative Liability - Retirement of Series B Preferred Share, June Two	120,249	'	120,249	'	'	'	'	'
Dividend paid to Seaside 88, LP, June Two	-12,274	'	-12,274	'	'	'	'	'
Common shares issued for consulting and legal services July	5,000	2	4,998	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	2,165	'	'	'	'	'	'
Collection of stock subscription receivable	100,000	'	0	100,000	'	'	'	'
Common shares issued for consulting services, July	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, July (in shares)	'	2,424	'	'	'	'	'	'
Payment of Finder's Fee	-5,250	0	-5,250	'	'	'	'	'
Common shares issued for consulting services, August	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, August (in shares)	'	1,661	'	'	'	'	'	'
Common shares issued for consulting services, October	5,600	2	5,598	'	'	'	'	'
Common shares issued for consulting services, October (in shares)	'	2,195	'	'	'	'	'	'
Common shares issued for consulting services, November	8,400	3	8,397	'	'	'	'	'
Common shares issued for consulting services, November (in shares)	'	2,791	'	'	'	'	'	'
Common shares issued for consulting services, December	8,400	3	8,397	'	'	'	'	'
Common shares issued for consulting services, December (in shares)	'	2,833	'	'	'	'	'	'
Common shares issued for consulting services, February	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting services, February (in shares)	'	1,303	'	'	'	'	'	'
Common shares issued for consulting services, March	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting services, March (in shares)	'	1,008	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009	1,337,500	764	1,336,736	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009 (in shares)	'	764,286	'	'	'	'	'	'
Common shares and warrants issued in connection with warrant conversion, September 30, 2009	1,879,900	1,074	1,878,826	'	'	'	'	'
Common shares and warrants issued in connection with warrant conversion, September 30, 2009 (in shares)	'	1,074,229	'	'	'	'	'	'
Common shares issued for Legal services valued at $56.50 per share, October 26, 2009	7,063	4	7,059	'	'	'	'	'
Common shares issued for Legal services valued at $56.50 per share, October 26, 2009 (in shares)	'	3,571	'	'	'	'	'	'
Common shares issued for consulting and legal services valued at $ .57 per share, October 1, 2009	20,000	10	19,990	'	'	'	'	'
Common shares issued for consulting and legal services valued at $ .57 per share, October 1, 2009 (in shares)	'	10,025	'	'	'	'	'	'
Common shares issued upon conversion of Warrants, November 10, 2009	1,440	3	1,437	'	'	'	'	'
Common shares issued upon conversion of Warrants, November 10, 2009 (in shares)	'	2,857	'	'	'	'	'	'
Common shares issued in payment of accounts payable, November 25, 2009	25,200	9	25,191	'	'	'	'	'
Common shares issued in payment of accounts payable, November 25, 2009 (in shares)	'	9,286	'	'	'	'	'	'
Series A Preferred Shares issued for TheraCour license valued at $.001 par value, February 15, 2010	7,000	0	5,000	'	'	2,000	'	'
Series A Preferred Shares issued for TheraCour license valued at $.001 par value, February 15, 2010 (in shares)	'	0	'	'	'	2,000,000	'	'
Common shares issued in lieu of payment of accounts payable - All Sciences	31,700	11	31,689	'	'	'	'	'
Common shares issued in lieu of payment of accounts payable - All Sciences (in shares)	'	11,321	'	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, May 12, 2010	5,000,000	0	4,999,857	'	'	'	143	'
Series B Preferred Shares issued to SeaSide 88, LP, May 12, 2010 (shares)	'	0	'	'	'	'	142,857	'
Placement Agents Fees related to sale of Convertible Preferred shares, May 12, 2010	-400,000	0	-400,000	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, May 12, 2010	-50,000	0	-50,000	'	'	'	'	'
Common shares issued for consulting and legal services valued at $2.083 per share, May 31, 2010	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued at $2.083 per share, May 31, 2010 (in shares)	'	686	'	'	'	'	'	'
Common shares issued for conversion of warrants to Common Stock at $1.00 per share, June 9, 2010	195,000	55	194,945	'	'	'	'	'
Common shares issued for conversion of warrants to Common Stock at $1.00 per share, June 9, 2010 (in shares)	'	55,714	'	'	'	'	'	'
Common shares issued for consulting and legal services valued, June One	20,000	3	19,997	'	'	'	'	'
Common shares issued for consulting and legal services valued, June One (in shares)	'	3,229	'	'	'	'	'	'
Common shares issued for consulting and legal services valued, June Two	3,540	1	3,539	'	'	'	'	'
Common shares issued for consulting and legal services valued, June Two (in shares)	'	571	'	'	'	'	'	'
Common shares issued for consulting and legal services valued, June Three	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued, June Three (in shares)	'	782	'	'	'	'	'	'
Net loss	-4,744,208	'	0	'	-4,744,208	'	'	'
Balance at Jun. 30, 2010	6,518,677	38,280	23,217,895	0	-16,739,743	2,170	75	'
Balance (in shares) at Jun. 30, 2010	'	38,280,135	'	'	'	2,169,644	74,285	0
Common shares issued for conversion of Series B Preferred Shares, July One	397	113	284	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July One (in shares)	'	113,454	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One	-60	'	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One (in shares)	'	0	'	'	'	'	-17,143	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two	-60	'	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two (in shares)	'	0	'	'	'	'	-17,143	'
Dividend paid to Seaside 88, LP, July Two	-7,671	'	-7,671	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One	9,973	2	9,971	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One (in shares)	'	1,731	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two	463	132	331	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two (in shares)	'	132,336	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, July One	-9,973	'	-9,973	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July One	116,715	'	116,715	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July Two	113,700	'	113,700	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two	7,671	2	7,669	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two (in shares)	'	1,655	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For August	45,000	'	45,000	'	'	'	'	'
Common shares issued for consulting and legal services, August	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	1,152	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One	5,370	1	5,369	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One (in shares)	'	1,347	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One	527	151	376	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One (in shares)	'	150,547	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August One	104,480	'	104,480	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One	-60	'	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One (in shares)	'	0	'	'	'	'	-17,143	'
Dividend paid to Seaside 88, LP, August One	-5,370	'	-5,370	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two	606	173	433	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two (in shares)	'	173,248	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August Two	-60	'	-43	'	'	'	-17	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August Two (in shares)	'	0	'	'	'	'	-17,143	'
Dividend paid to Seaside 88, LP, August Two	-3,068	'	-3,068	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two	3,068	1	3,067	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two (in shares)	'	886	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August Two	104,795	'	104,795	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	1,335	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One	-20	'	-14	'	'	'	-6	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One (in shares)	'	0	'	'	'	'	-5,714	'
Common shares issued for conversion of Series B Preferred Shares, September One	215	62	153	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September One (in shares)	'	61,523	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One	767	0	767	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One (in shares)	'	219	'	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, For September	2,500,000	'	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, For September (in shares)	'	0	'	'	'	'	71,429	'
Placement Agents fees related to sale of Convertible Preferred shares, For September	-195,000	'	-195,000	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares ,September One	34,841	'	34,841	'	'	'	'	'
Legal fees related to sale of Convertible Preferred Stock, For September	-10,000	'	-10,000	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares	-328,086	'	-328,086	'	'	'	'	'
Dividend paid to Seaside 88, LP, September	-767	'	-767	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For September One	103,012	'	103,012	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two	430	123	307	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two (in shares)	'	122,861	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP,September Two (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP, October One	-8,055	'	-8,055	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares, October One	460	131	329	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October One (in shares)	'	131,499	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For October One	103,330	'	103,330	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One	8,055	3	8,052	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One (in shares)	'	2,648	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares, October Two	452	129	323	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October Two (in shares)	'	129,419	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two	6,521	2	6,519	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two (in shares)	'	2,110	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October Two	-6,521	'	-6,521	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, October Two	69,635	'	69,635	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	1,387	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One	461	132	329	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One (in shares)	'	131,804	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One (in shares)	'	0	'	'	'	'	-11,429	'
Series A Preferred Shares issued for employee stock compensation, For November	53,933	'	53,924	'	'	9	'	'
Series A Preferred Shares issued for employee stock compensation, For November (in shares)	'	0	'	'	'	8,571	'	'
Common shares issued as dividend to Seaside 88, LP, For November One	4,986	2	4,984	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November One (in shares)	'	1,643	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-4,986	'	-4,986	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For November One	69,104	'	69,104	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares per share, November Two	346	99	247	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Two (in shares)	'	98,805	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For November Two	69,187	'	69,187	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP, November Two	-3,452	'	-3,452	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two	3,452	1	3,451	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two (in shares)	'	853	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-4,986	'	-4,986	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three	311	89	222	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three (in shares)	'	88,733	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three (in shares)	'	0	'	'	'	'	-11,428	'
Dividend paid to Seaside 88, LP, November Three	-1,918	'	-1,918	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November Three	1,918	0	1,918	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November Three (in shares)	'	405	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For November Three	69,449	'	69,449	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	55,800	'	55,800	'	'	'	'	'
Common shares issued for consulting and legal services For November	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	979	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One	91	26	65	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, For December	-200,000	'	-200,000	'	'	'	'	'
Common shares issued for conversion of warrants to Common Stock For December	25,000	7	24,993	'	'	'	'	'
Common shares issued for conversion of warrants to Common Stock For December (in shares)	'	7,143	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One (in shares)	'	25,954	'	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, For December	2,500,000	'	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, For December (in shares)	'	0	'	'	'	'	71,429	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December	-10	'	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December (in shares)	'	0	'	'	'	'	-2,857	'
Common shares issued as compensation pursuant to S-8 For December	64,000	14	63,986	'	'	'	'	'
Common shares issued as compensation pursuant to S-8 For December (in shares)	'	14,286	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December	384	0	384	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December (in shares)	'	99	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, December One	17,438	'	17,438	'	'	'	'	'
Dividend paid to Seaside 88, LP, December One	-384	'	-384	'	'	'	'	'
Common shares issued for consulting and legal services For December	6,053	1	6,052	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	1,299	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares January One	344	98	246	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January One (in shares)	'	98,227	'	'	'	'	'	'
Common shares issued for consulting and legal services For January	6,000	1	5,999	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One	8,904	2	8,902	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One (in shares)	'	2,187	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For January One	73,532	'	73,532	'	'	'	'	'
Dividend paid to Seaside 88, LP January One	-8,904	'	-8,904	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two	318	91	227	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two (in shares)	'	90,847	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Two	-8,055	'	-8,055	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	8,055	2	8,053	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two (in shares)	'	1,829	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For January Two	70,882	'	70,882	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two (in shares)	'	0	'	'	'	'	-11,428	'
Derivative liability - retirement ofSeries B Preferred Shares For January Three	72,432	'	72,432	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, January Three	356	102	254	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, January Three (in shares)	'	101,835	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three	6,521	2	6,519	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three (in shares)	'	1,506	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Three	-6,521	'	-6,521	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three	-40	'	-29	'	'	'	-11	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three (in shares)	'	0	'	'	'	'	-11,429	'
Series A Preferred Shares issued for employee stock compensation March One	574,581	'	574,510	'	'	71	'	'
Series A Preferred Shares issued for employee stock compensation March One (in shares)	'	0	'	'	'	71,428	'	'
Common shares issued as dividend to Seaside 88, LP, March Two	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, March Two (in shares)	'	99	'	'	'	'	'	'
Common shares issued for consulting and legal services For January (in shares)	'	1,168	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	54,000	'	54,000	'	'	'	'	'
Common shares issued for conversion of warrants For February	25,000	7	24,993	'	'	'	'	'
Common shares issued for conversion of warrants For February (in shares)	'	7,143	'	'	'	'	'	'
Common shares issued for consulting and legal services February	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	1,401	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One	375	106	269	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One (in shares)	'	105,719	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One	4,986	1	4,985	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One (in shares)	'	1,318	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One (in shares)	'	0	'	'	'	'	-11,428	'
Dividend paid to Seaside 88, LP February One	-4,986	'	-4,986	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For February One	71,699	'	71,699	'	'	'	'	'
Dividend paid to Seaside 88, LP February Two	-3,452	'	-3,452	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two	409	116	293	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two (in shares)	'	115,889	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued as dividend to Seaside 88, LP February Two	3,452	1	3,451	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP February Two (in shares)	'	1,000	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares February Two	71,490	'	71,490	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One	367	105	262	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One (in shares)	'	104,935	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One	1,918	1	1,917	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One (in shares)	'	503	'	'	'	'	'	'
Dividend paid to Seaside 88, LP March One	-1,918	'	-1,918	'	'	'	'	'
Common shares issued for employee stock compensation for March One	158,125	36	158,089	'	'	'	'	'
Common shares issued for employee stock compensation for March One (in shares)	'	35,714	'	'	'	'	'	'
Common shares issued for employee stock compensation, March	158,125	36	158,089	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	35,714	'	'	'	'	'	'
Derivative Liability - Retirement of Series B Preferred Shares March One	70,566	'	70,566	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March	574,581	'	574,510	'	'	71	'	'
Series A Preferred Shares issued for employee stock compensation, March (in shares)	'	0	'	'	'	71,428	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for conversion of Series B Preferred Shares, March Two	90	26	64	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, March Two (in shares)	'	25,710	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March Two	215,468	'	215,441	'	'	27	'	'
Series A Preferred Shares issued for employee stock compensation, March Two (in shares)	'	0	'	'	'	26,786	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two	-10	'	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two (in shares)	'	0	'	'	'	'	-2,857	'
Derivative liability - retirement of Series B Preferred Shares, March Two	17,525	'	17,525	'	'	'	'	'
Common shares issued for consulting and legal services, For March	6,000	1	5,999	'	'	'	'	'
Dividend paid to Seaside 88, LP March Two	-384	'	-384	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	1,337	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	1,168	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares April One	40	89	-49	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, April One (in shares)	'	89,189	'	'	'	'	'	'
Common shares issued for conversion of warrants to common stock, April	10,000	3	9,997	'	'	'	'	'
Common shares issued for conversion of warrants to common stock, April (in shares)	'	2,857	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One (in shares)	'	0	'	'	'	'	-11,429	'
Series B Preferred Shares issued to SeaSide 88, LP, April	2,500,000	'	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, April (in shares)	'	0	'	'	'	'	71,429	'
Legal fees related to Sale of Convertible Preferred Stock, April	-25,000	'	-25,000	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, April One	68,756	'	68,756	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, April	-160,000	'	-160,000	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares, Two	-429,725	'	-429,725	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One	40	97	-57	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One (in shares)	'	97,065	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	50,400	'	50,400	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One	8,055	2	8,053	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One (in shares)	'	1,955	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for consulting and legal services, May	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	1,168	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, May One	-8,055	'	-8,055	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May One	68,941	'	68,941	'	'	'	'	'
Dividend paid to Seaside 88, LP, May Two	-6,521	'	-6,521	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Two	40	96	-56	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Two (in shares)	'	96,143	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Two (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued as dividend to Seaside 88, LP, May Two	6,521	2	6,519	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May Two (in shares)	'	1,554	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May Two	69,194	'	69,194	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, May Three	4,986	1	4,985	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, May Three (in shares)	'	1,163	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Three	40	93	-53	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May Three (in shares)	'	93,280	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Three	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May Three (in shares)	'	0	'	'	'	'	-11,428	'
Dividend paid to Seaside 88, LP, May Three	-4,986	'	-4,986	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May Three	69,464	'	69,464	'	'	'	'	'
Dividend paid to Seaside 88, LP, June One	-3,452	'	-3,452	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, June One	3,452	1	3,451	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, June One (in shares)	'	838	'	'	'	'	'	'
Common shares issued for consulting and legal services, June	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	1,401	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June One	40	97	-57	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June One (in shares)	'	97,135	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June One (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - retirement of Series B Preferred Shares, June One	69,727	'	69,727	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June Two	40	112	-72	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, June Two (in shares)	'	111,957	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June Two	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, June Two (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued as Dividend to Seaside 88, LP June Two	1,918	0	1,918	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP June Two (in shares)	'	497	'	'	'	'	'	'
Derivative Liability - Retirement of Series B Preferred Share, June Two	69,973	'	69,973	'	'	'	'	'
Dividend paid to Seaside 88, LP, June Two	-1,918	'	-1,918	'	'	'	'	'
Common shares issued for consulting and legal services valued, July One	5,000	1	4,999	'	'	'	'	'
Common shares issued for consulting and legal services valued, July One (in shares)	'	882	'	'	'	'	'	'
Net loss	-6,477,166	'	0	'	-6,477,166	'	'	'
Balance at Jun. 30, 2011	10,170,891	41,012	33,344,437	0	-23,216,909	2,348	3	'
Balance (in shares) at Jun. 30, 2011	'	41,013,828	'	'	'	2,347,857	2,857	'
Common shares issued for conversion of Series B Preferred Shares, July One	90	26	64	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July One (in shares)	'	25,710	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One	-10	'	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One (in shares)	'	0	'	'	'	'	-2,857	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued as dividend to Seaside 88, LP, July One	381	0	381	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One (in shares)	'	99	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two	378	108	270	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two (in shares)	'	107,943	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, July One	-381	'	-381	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July One	17,881	'	17,881	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July Two	68,425	'	68,425	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, July	2,500,000	'	2,499,929	'	'	'	71	'
Series B Preferred Shares Issued During Period Issued For July	'	0	'	'	'	'	71,429	'
Warrants issued to Scientific Advisory Board, For August	56,400	'	56,400	'	'	'	'	'
Common shares issued for consulting and legal services, August	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	1,504	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One	8,055	2	8,053	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One (in shares)	'	2,345	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One	437	125	312	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One (in shares)	'	124,911	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August One	69,193	'	69,193	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, August	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, August (in shares)	'	0	'	'	'	'	-11,428	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP, August One	-8,055	'	-8,055	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two	420	120	300	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two (in shares)	'	119,951	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, August Two	-6,521	'	-6,521	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two	6,521	2	6,519	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two (in shares)	'	1,955	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August Two	69,351	'	69,351	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	1,602	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for conversion of Series B Preferred Shares, September One	423	121	302	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September One (in shares)	'	120,821	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One	4,986	2	4,984	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One (in shares)	'	1,504	'	'	'	'	'	'
Series A Preferred Shares amendment of valuation arising from Amendment of certificate of Designation, June	0	0	0	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares ,September One	69,887	'	69,887	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two	3,452	0	3,452	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two (in shares)	'	1,055	'	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares	-430,283	0	-430,283	'	'	'	'	'
Dividend paid to Seaside 88, LP, September	-4,986	'	-4,986	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two	428	122	306	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two (in shares)	'	122,186	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP,September Two (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - retirement of Series B Preferred Shares, For September Two	69,970	'	69,970	'	'	'	'	'
Dividend to Seaside 88, LP, paid September Two	-3,452	'	-3,452	'	'	'	'	'
Dividend paid to Seaside 88, LP, October One	-1,918	0	-1,918	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for conversion of Series B Preferred Shares, October One	514	147	367	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October One (in shares)	'	146,946	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For October One	69,496	0	69,496	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One	1,918	1	1,917	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One (in shares)	'	649	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two (in shares)	'	0	'	'	'	'	-2,857	'
Common shares issued for conversion of Series B Preferred Shares, October Two	144	41	103	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October Two (in shares)	'	41,281	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two (in shares)	'	146	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October Two	-384	0	-384	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, October Two	17,790	0	17,790	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	1,868	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One	579	165	414	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One (in shares)	'	165,313	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One (in shares)	'	0	'	'	'	'	-11,429	'
Placement Agents Fees related to sale of Convertible Preferred shares, November	-160,000	0	-160,000	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, November	2,500,000	0	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, November (in shares)	'	0	'	'	'	'	71,429	'
Common shares issued as dividend to Seaside 88, LP, For November One	7,479	3	7,476	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November One (in shares)	'	2,946	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-7,479	0	-7,479	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For November One	68,297	0	68,297	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares per share, November Two	579	165	414	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Two (in shares)	'	183,639	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For November Two	68,411	0	68,411	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two (in shares)	'	0	'	'	'	'	-11,428	'
Dividend paid to Seaside 88, LP, November Two	-6,521	0	-6,521	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two	6,521	3	6,518	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-7,479	0	-7,479	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three	643	184	459	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three (in shares)	'	2,897	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - Retirement of Series B Preferred Shares, For November Three	68,591	0	68,591	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	56,400	0	56,400	'	'	'	'	'
Common shares issued for consulting and legal services For November	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	2,107	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One	751	215	536	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One (in shares)	'	214,661	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December (in shares)	'	0	'	'	'	'	-11,429	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December One	-40	0	-28	'	'	'	-12	'
Common shares issued as Dividend to Seaside 88, LP, December	4,986	3	4,983	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December (in shares)	'	2,514	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, For December One	3,450	2	3,448	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, For December One (in shares)	'	1,948	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, December	-4,986	0	-4,986	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C	-1,090,017	0	-1,090,017	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, December	68,753	0	68,753	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, December One	68,965	0	68,965	'	'	'	'	'
Dividend paid to Seaside 88, LP, December One	-3,452	0	-3,452	'	'	'	'	'
Common shares issued for consulting and legal services For December	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	2,687	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares January One	788	225	563	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January One (in shares)	'	225,158	'	'	'	'	'	'
Common shares issued for consulting and legal services For January	6,000	3	5,997	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One	1,918	1	1,917	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One (in shares)	'	1,069	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January One	69,222	0	69,222	'	'	'	'	'
Dividend paid to Seaside 88, LP January One	-1,918	0	-1,918	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two	209	60	149	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two (in shares)	'	59,585	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Two	-384	0	-384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two (in shares)	'	225	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For January Two	69,883	0	69,883	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two (in shares)	'	0	'	'	'	'	-2,857	'
Placement Agents Fees related to sale of Convertible Preferred shares, February	-150,000	0	-150,000	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, March Two	4,986	2	4,984	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, March Two (in shares)	'	2,232	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April (in shares)	'	0	'	'	'	'	-11,429	'
Series B Preferred Shares issued to SeaSide 88, LP, February	2,500,000	0	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, February (in shares)	'	0	'	'	'	'	71,429	'
Common shares issued for consulting and legal services For January (in shares)	'	2,962	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	51,000	0	51,000	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, February	-6,250	0	-6,250	'	'	'	'	'
Common shares issued for consulting and legal services February	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	2,219	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One	717	205	512	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One (in shares)	'	204,898	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One	7,479	3	7,476	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One (in shares)	'	3,314	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP February One	-7,479	0	-7,479	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For February One	68,169	0	68,169	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two	576	165	411	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two (in shares)	'	164,589	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two (in shares)	'	0	'	'	'	'	-11,428	'
Derivative liability - retirement of Series B Preferred Shares February Two	68,423	0	68,423	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One	628	180	448	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One (in shares)	'	179,511	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One	6,521	3	6,518	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One (in shares)	'	2,926	'	'	'	'	'	'
Dividend paid to Seaside 88, LP March One	-6,521	0	-6,521	'	'	'	'	'
Common shares issued for employee stock compensation, March	181,874	71	181,803	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	71,429	'	'	'	'	'	'
Derivative Liability - Retirement of Series B Preferred Shares March One	68,602	0	68,602	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March	634,408	0	634,239	'	'	169	'	'
Series A Preferred Shares issued for employee stock compensation, March (in shares)	'	0	'	'	'	169,643	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares, March Two	636	182	454	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, March Two (in shares)	'	181,712	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - retirement of Series B Preferred Shares, March Two	68,862	0	68,862	'	'	'	'	'
Common shares issued for consulting and legal services, For March	6,000	2	5,998	'	'	'	'	'
Dividend paid to Seaside 88, LP March Two	-4,986	0	-4,986	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	2,208	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	2,728	'	'	'	'	'	'
Shares issued in conversion of Series B Preferred Shares to Common Stock, April (in shares)	'	188,999	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares April One	785	224	561	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, April One (in shares)	'	224,415	'	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April	3,452	2	3,450	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April (in shares)	'	1,631	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One (in shares)	'	0	'	'	'	'	-11,429	'
Shares issued in conversion of Series B Preferred Shares to Common Stock, April	661	189	472	'	'	'	'	'
Dividend to Seaside 88, LP, April One	-1,918	0	-1,918	'	'	'	'	'
Dividend to Seaside 88, LP, April	-3,452	0	-3,452	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, April One	69,224	0	69,224	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series B, April	69,098	0	69,098	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April One	1,918	1	1,917	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April One (in shares)	'	1,023	'	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares, Two	-429,768	'	-429,768	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One	199	57	142	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One (in shares)	'	56,673	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	47,400	0	47,400	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One (in shares)	'	215	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One (in shares)	'	0	'	'	'	'	-2,857	'
Common shares issued for consulting and legal services, May	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	2,561	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, May One	-384	0	-384	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May One	69,892	0	69,892	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, June	2,500,000	0	2,499,999	'	'	'	'	1
Series C Preferred Shares issued to SeaSide 88, LP, June (in shares)	'	0	'	'	'	'	'	714
Legal Fees related to Sale of Convertible Preferred Stock, June	-25,000	0	-25,000	'	'	'	'	'
Common shares issued for consulting and legal services, June	5,999	2	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	2,814	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, June	298	85	213	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, June (in shares)	'	85,278	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, June	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, June (in shares)	'	0	'	'	'	'	'	-42
Series A Preferred Shares issued for employee stock compensation, June One	345,172	0	344,872	'	'	300	'	'
Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued For June One	'	0	'	'	'	300,000	'	'
Derivative Liability - Retirement of Preferred Series C, June	63,704	0	63,704	'	'	'	'	'
Shares of Series A Preferred issued for legal services	3,287	0	3,284	'	'	3	'	'
Shares of Series A Preferred issued for legal services (in shares)	'	0	'	'	'	2,857	'	'
Placement Agents Fees related to sale of Convertible Preferred shares, June	-150,000	0	-150,000	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP December One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for consulting and legal services July	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	1,361	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series B,November	-429,804	0	-429,804	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, November	-25,000	0	-25,000	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November	512	146	366	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November (in shares)	'	146,225	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December Two	798	228	570	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December Two (in shares)	'	227,653	'	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, July 26, 2011	-150,000	'	-150,000	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, July 26, 2011	-6,250	'	-6,250	'	'	'	'	'
Net loss	-6,207,207	0	0	'	-6,207,207	'	'	'
Balance at Jun. 30, 2012	13,850,193	44,460	43,227,028	0	-29,424,116	2,820	0	1
Balance (in shares) at Jun. 30, 2012	'	44,460,629	'	'	'	2,820,357	'	672
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July Two (in shares)	'	0	'	'	'	'	'	-37
Dividend paid to Seaside 88, LP, July Two	-8,629	0	-8,629	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July One	212	61	151	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July One (in shares)	'	60,685	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One	9,026	5	9,021	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One (in shares)	'	5,256	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, July One	-9,026	0	-9,026	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, July One	44,190	0	44,190	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July One	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July One (in shares)	'	0	'	'	'	'	'	-29
Shares issued in conversion of Series C Preferred Shares to Common Stock, July Two	271	78	193	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July Two (in shares)	'	77,535	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July Two	53,032	0	53,032	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two	8,629	5	8,624	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two (in shares)	'	5,221	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For August	40,800	0	40,800	'	'	'	'	'
Common shares issued for consulting and legal services, August	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	2,956	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One	8,138	5	8,133	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One (in shares)	'	5,391	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August One (in shares)	'	0	'	'	'	'	'	-34
Shares issued in conversion of Series C Preferred Shares to Common Stock, August One	281	80	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August One (in shares)	'	80,270	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, August One	-8,138	0	-8,138	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, August One	51,555	0	51,555	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August Two	575	164	411	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August Two (in shares)	'	164,226	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August Two (in shares)	'	0	'	'	'	'	'	-79
Dividend paid to Seaside 88, LP, August Two	-7,684	0	-7,684	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two	7,684	5	7,679	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two (in shares)	'	4,573	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, August Two	121,054	0	121,054	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	2,765	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September One	763	218	545	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September One (in shares)	'	218,039	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One	-1	0	0	'	'	'	'	-1
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One (in shares)	'	0	'	'	'	'	'	-126
Common shares issued as dividend to Seaside 88, LP, September One	6,625	3	6,622	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One (in shares)	'	3,279	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two	4,936	3	4,933	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two (in shares)	'	2,735	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, September Two	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, September Two (in shares)	'	0	'	'	'	'	'	-81
Dividend paid to Seaside 88, LP, September	-6,625	0	-6,625	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For September One	236,481	0	236,481	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September Two	553	158	395	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September Two (in shares)	'	158,096	'	'	'	'	'	'
Dividend to Seaside 88, LP, paid September Two	-4,936	0	-4,936	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C , September Two	182,575	0	182,575	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October One	436	125	311	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October One (in shares)	'	124,526	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October One	-2,948	0	-2,948	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October One (in shares)	'	0	'	'	'	'	'	-67
Common shares issued as dividend to Seaside 88, LP, For October One	3,842	2	3,840	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One (in shares)	'	2,050	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October One	39,945	0	39,945	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Two	312	89	223	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Two (in shares)	'	89,006	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Two (in shares)	'	0	'	'	'	'	'	-47
Common shares issued as dividend to Seaside 88, LP, October Two	2,948	2	2,946	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two (in shares)	'	1,586	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October Two	-2,313	0	-2,313	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October Two	28,413	0	28,413	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Three	281	80	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Three (in shares)	'	80,385	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Three	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Three (in shares)	'	0	'	'	'	'	'	-41
Shares issued as Dividend to Seaside 88, LP, October Three	2,313	1	2,312	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, October Three (in shares)	'	1,280	'	'	'	'	'	'
Dividend to Seaside 88, LP, paid, October One	-3,842	0	-3,842	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October Three	24,955	0	24,955	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	10,000	5	9,995	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	4,751	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November One	383	109	274	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November One (in shares)	'	109,470	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November One (in shares)	'	0	'	'	'	'	'	-47
Common shares issued as dividend to Seaside 88, LP, For November One	1,756	1	1,755	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November One (in shares)	'	1,092	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-1,756	0	-1,756	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, November One	28,407	0	28,407	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November Two	-1	0	-1	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November Two (in shares)	'	0	'	'	'	'	'	-49
Shares issued in conversion of Series C Preferred Shares to Common Stock, November Two	391	112	279	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November Two (in shares)	'	111,628	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, November Two	29,302	0	29,302	'	'	'	'	'
Dividend paid to Seaside 88, LP, November Two	-1,121	0	-1,121	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two	1,121	1	1,120	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two (in shares)	'	734	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-1,756	0	-1,756	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	34,200	0	34,200	'	'	'	'	'
Common shares issued for consulting and legal services For November	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	3,774	'	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, For December	-165,000	0	-165,000	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December One	282	81	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December One (in shares)	'	80,680	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December One	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December One (in shares)	'	0	'	'	'	'	'	-35
Legal Fees related to Sale of Convertible Preferred Stock, December	-12,500	0	-12,500	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December	468	0	468	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December (in shares)	'	309	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C	0	0	0	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December Two	357	102	255	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December Two (in shares)	'	102,080	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December Two (in shares)	'	0	'	'	'	'	'	-45
Derivative liability - retirement of Series C Preferred Shares, December One	20,953	0	20,953	'	'	'	'	'
Dividend paid to Seaside 88, LP, December One	-468	0	-468	'	'	'	'	'
Shares issued to a Director for services rendered at $0.55 per share December	5,000	3	4,997	'	'	'	'	'
Shares issued to a Director for services rendered December (in shares)	'	2,581	'	'	'	'	'	'
Common shares issued for consulting and legal services For December	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	4,000	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C, December Two	24,686	0	24,686	'	'	'	'	'
Common shares issued for consulting and legal services For January	7,000	4	6,996	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January One (in shares)	'	0	'	'	'	'	'	-41
Common shares issued for conversion of Series C Preferred Shares January One	350	100	250	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January One (in shares)	'	99,998	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One	8,992	6	8,986	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One (in shares)	'	6,259	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January One	22,488	0	22,488	'	'	'	'	'
Dividend paid to Seaside 88, LP January One	-8,992	0	-8,992	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	388	111	277	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January Two (in shares)	'	110,842	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Two	-8,441	0	-8,441	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	8,441	6	8,435	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two (in shares)	'	5,714	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January Two	26,329	0	26,329	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Two (in shares)	'	0	'	'	'	'	'	-47
Common shares issued for conversion of Series C Preferred Shares January Three	276	79	197	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January Three (in shares)	'	78,797	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three	7,813	5	7,808	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three (in shares)	'	5,400	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Three	-7,813	0	-7,813	'	'	'	'	'
Derivative liability - retirement ofSeries C Preferred Shares For January Three	18,502	0	18,502	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three (in shares)	'	0	'	'	'	'	'	-32
Derivative liability - retirement of Series C Preferred Shares For February One	15,985	0	15,985	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation March One	445,044	0	444,874	'	'	170	'	'
Series A Preferred Shares issued for employee stock compensation March One (in shares)	'	0	'	'	'	169,643	'	'
Common shares issued for consulting and legal services For January (in shares)	'	4,082	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	31,800	0	31,800	'	'	'	'	'
Common shares issued for consulting and legal services February	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	4,348	'	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares February One	241	69	172	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares February One (in shares)	'	68,875	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP February One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP February One (in shares)	'	0	'	'	'	'	'	-27
Dividend paid to Seaside 88, LP February One	-7,376	0	-7,376	'	'	'	'	'
Dividend paid to Seaside 88, LP February Two	-6,002	0	-6,002	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP February Two	7,376	5	7,371	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP February Two (in shares)	'	5,172	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares February Two	42	0	42	'	'	'	'	'
Common shares issued for employee stock compensation, March	60,000	71	59,929	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	71,428	'	'	'	'	'	'
Common shares issued for consulting and legal services, For March	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	3,077	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	960	1	959	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	569	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	34,800	0	34,800	'	'	'	'	'
Common shares issued for consulting and legal services, May	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	3,333	'	'	'	'	'	'
Common shares issued for consulting and legal services, June	6,996	3	6,993	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	3,030	'	'	'	'	'	'
Shares issued to a Director for services rendered at $0.55 per share	2,500	2	2,498	'	'	'	'	'
Shares issued to a Director for services rendered (in shares)	'	1,348	'	'	'	'	'	'
Common shares issued for consulting and legal services July	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	3,117	'	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, December	2,541,872	0	2,541,872	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, December (in shares)	'	0	'	'	'	'	'	714
Shares issued in payment of Debenture interest on February	665,497	571	664,926	'	'	'	'	'
Shares issued in payment of Debenture interest on February (in shares)	'	571,429	'	'	'	'	'	'
Redemption of Series C Convertible Preferred on February	-1,714,334	0	-1,714,334	'	'	'	'	'
Redemption of Series C Convertible Preferred on February (in shares)	'	'	'	'	'	'	'	-522
Common shares issued for consulting and legal services, April One	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, April One (in shares)	'	3,175	'	'	'	'	'	'
Shares issued for Directors fees on June	11,250	5	11,245	'	'	'	'	'
Shares issued for Directors fees on June (in shares)	'	4,592	'	'	'	'	'	'
Net loss	-8,875,668	0	0	'	-8,875,668	'	'	'
Balance at Jun. 30, 2013	8,009,652	47,026	46,259,420	0	-38,299,784	2,990	0	0
Balance (in shares) at Jun. 30, 2013	'	47,026,173	'	'	'	2,990,000	'	0
Warrants issued to Scientific Advisory Board, For August	106,050	0	106,050	'	'	'	'	'
Common shares issued for consulting and legal services, August	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	3,449	'	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	3,226	'	'	'	'	'	'
Common shares issued for consulting and legal services July	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	3,627	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009	10,308,996	2,945	10,306,051	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009 (in shares)	'	2,945,428	'	'	'	'	'	'
Costs associated with sale of Securities	-113,696	'	-113,696	'	'	'	'	'
Warrants issued for commissions, September 10, 2013	113,696	0	113,696	'	'	'	'	'
Placement Agents Fees related to sale of Common shares and Warrants on September 10, 2013	-618,545	0	-618,545	'	'	'	'	'
Common shares issued to round up fractional shares resulting from reverse split	0	6	-6	'	'	'	'	'
Common shares issued to round up fractional shares resulting from reverse split (in shares)	'	5,940	'	'	'	'	'	'
Common Shares issued in connection with warrant conversion, September 25, 2013	185,624	35	185,589	'	'	'	'	'
Common Shares issued in connection with warrant conversion, September 25, 2013 (in shares)	'	35,357	'	'	'	'	'	'
Shares issued for Directors fees at $2.04 per share on September 30, 2013	11,250	6	11,244	'	'	'	'	'
Shares issued for Directors fees at $2.04 per share on September 30, 2013 (in shares)	'	5,501	'	'	'	'	'	'
Net loss	-6,272,780	0	0	'	-6,272,780	'	'	'
Balance at Sep. 30, 2013	11,751,247	50,029	56,270,792	0	-44,572,564	2,990	0	0
Balance (in shares) at Sep. 30, 2013	'	50,028,701	'	'	'	2,990,000	0	0
Common shares issued for consulting and legal services valued, For October	7,000	1	6,999	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	1,323	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	31,552	0	31,552	'	'	'	'	'
Common shares issued for consulting and legal services For November	7,000	1	6,999	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	1,362	'	'	'	'	'	'
Common shares issued for consulting and legal services For December	7,001	2	6,999	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	1,383	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, October 1, 2013	36,000	0	35,995	'	'	5	'	'
Series A Preferred Shares issued for employee stock compensation, October 1, 2013 (in shares)	'	0	'	'	'	5,117	'	'
Common Shares issued in connection with warrant conversion, December 16, 2013	25,000	7	24,993	'	'	'	'	'
Common Shares issued in connection with warrant conversion, December 16, 2013 (in shares)	'	7,143	'	'	'	'	'	'
Shares issued for Directors fees at $5.07 per share on December 31, 2013	11,250	2	11,248	'	'	'	'	'
Shares issued for Directors fees at $5.07 per share on December 31, 2013 (in shares)	'	2,220	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, October 1, 2013	27,000	0	26,998	'	'	2	'	'
Series A Preferred Shares issued for employee stock compensation, October 1, 2013 (in shares)	'	0	'	'	'	1,495	'	'
Net loss	-1,692,382	0	'	'	-1,692,382	'	'	'
Balance at Dec. 31, 2013	$10,210,668	$50,042	$56,422,575	$0	($46,264,946)	$2,997	$0	$0
Balance (in shares) at Dec. 31, 2013	'	50,042,132	'	'	'	2,996,612	0	0

Statement_of_Stockholders_Equi1

Statement of Stockholders' Equity [Parenthetical] (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2012	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2009	Jun. 30, 2008	Jun. 30, 2007	Jun. 30, 2006
Price per share of common stock issued for consulting and legal services, July One	'	'	'	'	'	$2.09	$0.66	$1.22	'	'	'
Price per share of common stock issued for consulting services, July One	'	'	$1.93	'	'	'	$0.66	$1.22	'	'	'
Price per share of common stock issued for consulting and legal services, August One	'	'	'	'	'	$1.24	$0.86	'	'	'	'
Price per share of common stock issued for consulting services, August One	'	'	$2.03	'	'	'	$0.86	$1.24	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, February One	'	'	'	'	$0.56	$1.08	'	'	'	'	'
Price per share of common stock issued for consulting services, September One	'	'	$2.17	'	'	'	$0.89	$1	'	'	$0.08
Price per share of common stock issued for consulting and legal services, October One	'	'	'	'	'	$1.03	$0.57	$0.71	'	'	'
Price per share of common stock issued for consulting and legal services, October Two	'	'	'	'	'	'	$0.73	'	'	'	'
Price per share of common stock issued for consulting services, October One	'	'	'	'	'	'	$0.89	$0.71	'	'	'
Price per share of common stock issued for consulting services, February One	'	'	'	'	'	'	$1.10	'	'	'	'
Price per share of common stock issued for consulting and legal services, November One	'	'	'	'	'	$1.46	$0.86	$0.67	'	'	'
Price per share of common stock issued for consulting services, November One	'	'	'	'	'	'	$0.86	$0.67	'	'	'
Price per share of common stock issued for consulting services, December One	'	'	'	'	'	'	$0.85	$0.83	'	'	'
Price per share of common stock issued for consulting and legal services, December One	'	'	'	'	'	$1.32	$0.85	$0.83	$0.49	'	'
Price per share of common stock issued for consulting and legal services, January One	'	'	'	'	'	$1.47	$1.04	$0.78	'	'	'
Price per share of common stock issued for legal services, October	'	'	'	'	'	'	$56.50	'	'	'	'
Price per share of common stock issued for consulting services, February Two	'	'	'	'	'	'	'	$0.71	'	'	'
Price per share of common stock issued for consulting and legal services, February One	'	'	'	'	'	$1.22	'	$0.71	'	'	'
Price per share of common stock issued for consulting services, March One	'	'	'	'	'	'	$1.42	$0.67	'	'	'
Price per share of common stock issued for consulting and legal services, March One	'	'	'	'	'	$1.28	$1.25	$0.67	$0.45	'	'
Price per share of common stock issued for consulting services, April One	'	'	'	'	'	'	'	$0.69	$0.39	'	'
Price per share of common stock issued for consulting and legal services, April One	'	'	'	'	'	$1.47	$2.09	$0.69	'	'	'
Price per share of common stock issued for consulting and legal services, May One	'	'	'	'	'	$1.47	$2.08	$0.66	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, November Two	'	'	'	$0.44	'	'	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, September One	'	'	'	'	'	$1.07	$0.89	'	$0.75	'	'
StockIssued During December For Legal Services One Price Per Share	'	'	'	'	'	'	'	'	'	'	$0.95
Price per share of common stock issued for consulting services, January One	'	'	'	'	'	'	'	$0.78	'	$0.76	$1.46
Price per share of common stock issued for consulting services, June One	'	'	'	'	'	'	'	$0.61	$1.03	$1.03	'
Price per share of common stock issued for consulting services, June Two	'	'	'	'	'	'	'	$0.56	'	$1.15	'
Price per share of common stock issued for consulting services, June Three	'	'	'	'	'	'	'	'	'	$1.06	'
Price per share of common stock issued to acquire equipment	'	'	'	'	'	'	'	$0.79	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, July One	'	'	'	'	$1.11	$1.51	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, July One	'	'	'	$0.49	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, July One	'	'	'	$0.49	$1.18	$1.65	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, July Two	'	'	'	'	$1.18	$1.30	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, July Two	'	'	'	$0.47	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, July Two	'	'	'	$0.47	'	$1.32	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, July	'	'	'	$0.55	$1.26	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, August One	'	'	'	'	$0.92	$1.14	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, August One	'	'	'	$0.42	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, August One	'	'	'	$0.43	$0.98	$1.14	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, August Two	'	'	'	'	$0.95	$0.99	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, August Two	'	'	'	$0.48	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, August Two	'	'	'	$0.43	$0.95	$0.99	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, August	'	'	'	$0.58	$1.14	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, September One	'	'	'	'	$0.95	$0.93	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, September One	'	'	'	$0.58	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, September One	'	'	'	$0.58	$0.95	$1	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, September Two	'	'	'	'	$0.94	$0.93	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, September Two	'	'	'	$0.52	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, September Two	'	'	'	$0.52	$0.94	'	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, September	'	'	'	$0.62	$1.07	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, October One	'	'	'	'	$0.78	$0.87	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, October One	'	'	'	$0.54	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, October One	'	'	'	$0.54	$0.85	$0.87	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, October Two	'	'	'	'	$0.69	$0.88	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, October Two	'	'	'	$0.53	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, October Two	'	'	'	$0.53	$0.75	$0.88	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, October Three	'	'	'	$0.52	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, October Three	'	'	'	$0.53	'	'	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, October	'	$5.29	'	$0.61	$0.92	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, November One	'	'	'	'	$0.78	$0.87	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, November One	'	'	'	$0.43	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, November One	'	'	'	'	$0.73	$0.87	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, November Two	'	'	'	$0.43	$0.69	$1.16	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, June One	'	'	'	'	'	$1.18	$1.41	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, November Two	'	'	'	$0.44	$0.64	$1.16	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, November Three	'	'	'	'	$0.62	$1.35	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, November Three	'	'	'	'	'	$1.35	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, November	'	$5.14	'	$0.53	$0.81	'	'	'	'	'	'
Price per share of common stock issued for conversion of warrants to Common stock, December	'	'	'	'	'	$1	'	'	'	'	'
Price per share of common stock issued for compensation pursuant	'	'	'	'	'	$1.28	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, December One	'	'	'	'	$0.53	$1.10	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, December One	'	'	'	$0.43	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, December One	'	'	'	$0.43	$0.57	$1.10	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, December Two	'	'	'	'	$0.51	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, December Two	'	'	'	$0.44	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, December Two	'	'	'	'	$0.57	'	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, December	$0.64	$5.01	'	$0.50	'	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, January One	'	'	'	'	$0.51	$1.16	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, January One	'	'	'	$0.41	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, January One	'	'	'	$0.41	$0.51	$1.16	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, January Two	'	'	'	'	$0.48	$1.26	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock january Two	'	'	'	$0.42	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, January Two	'	'	'	$0.42	$0.49	$1.26	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, January Three	'	'	'	'	'	$1.12	'	'	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, January Three	'	'	'	$0.42	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, January Three	'	'	'	$0.41	'	$1.24	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, January	'	'	'	$0.49	$0.58	'	'	'	'	'	'
Price per share of common stock issued for conversion of warrants to Common stock, February	'	'	'	'	'	$1	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, June One	'	'	'	'	$0.61	$1.22	$1.77	$0.56	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, February One	'	'	'	$0.41	'	'	'	'	'	'	'
Price per share of common stock issued for payment of debenture interest stock, February	'	'	'	$0.48	'	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, February One	'	'	'	$0.41	'	$1.08	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, February Two	'	'	'	'	$0.69	$0.99	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, February Two	'	'	'	'	$0.69	$0.99	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, February	'	'	'	$0.46	$0.77	'	'	'	'	'	'
Price per share of common stock issued for employee stock compensation, March One	'	'	'	'	$0.73	$1.32	$1.25	'	'	'	'
Price per share of common stock issued for employee stock compensation, March Two	'	'	'	$0.48	$0.73	$1.32	$1.25	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, March One	'	'	'	'	$0.64	$1.09	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, March One	'	'	'	'	$0.64	$1.09	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, March Two	'	'	'	'	$0.63	$1.11	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, March Two	'	'	'	'	$0.64	$1.11	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, March	'	'	'	$0.65	$0.78	'	'	'	'	'	'
Price per share of common stock issued for director services rendered, March	'	'	'	$0.53	'	'	'	'	'	'	'
Price per share of common stock issued for conversion of warrants to Common stock, April	'	'	'	'	'	$1	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, April One	'	'	'	'	$0.61	$1.28	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, April One	'	'	'	'	$0.61	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, April Two	'	'	'	'	$0.51	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, April Two	'	'	'	'	$0.54	'	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, April	'	'	'	'	$0.63	'	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, May One	'	'	'	'	$0.50	$1.18	$1.88	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, May One	'	'	'	'	$0.51	$1.18	$1.64	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, May Two	'	'	'	'	'	$1.19	$1.51	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, May Two	'	'	'	'	'	$1.20	'	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, May Three	'	'	'	'	'	$1.23	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, May Three	'	'	'	'	'	$1.23	'	'	'	'	'
Price per share of common stock issued for consulting and legal services, May	'	'	'	'	$0.67	'	'	'	'	'	'
Price per share of common stock issued for consulting services, May One	'	'	'	'	'	'	'	$0.66	'	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, June One	'	'	'	'	$0.49	'	'	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, June One	'	'	'	'	'	$1.18	$1.41	'	'	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, June Two	'	'	'	'	'	$1.02	$1.59	'	'	'	'
Price per share of common stock issued for dividend to seaside 88, June Two	'	'	'	'	'	$1.10	$1.59	'	'	'	'
Price per share of common stock issued for legal services, August One	'	'	'	'	'	'	'	$1.24	'	'	'
Price per share of common stock issued for legal services, September One	'	'	'	'	'	'	'	$1	'	'	'
Price per share of common stock issued for legal services, January One	'	'	'	'	'	'	'	$0.60	'	'	'
Price per share of common stock issued for employee stock compensation, March One	'	'	'	'	'	'	$1.25	'	'	'	'
Price per share of common stock issued for employee stock compensation, March Two	'	'	'	'	'	'	$1.25	'	'	'	'
Stock Issued During June For Conversion Of Warrants To Common Stock One Price Per Share	'	'	'	'	'	'	$1	'	'	'	'
Price per share of common stock issued for consulting and legal services, June Two	'	'	'	'	'	'	$1.77	'	'	'	'
Price per share of common stock issued for consulting and legal services, June Three	'	'	'	'	'	'	$1.04	'	'	'	'
Stock Issued During September For Director Services Rendered Price Per Share	'	'	$2.04	'	'	'	'	'	'	'	'
Stock Issued During December For Director Services Rendered Price Per Share	'	$5.07	'	$0.55	'	'	'	'	'	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended		104 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($7,965,162)	($3,012,340)	($46,264,946)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Preferred shares issued for license	0	0	7,000
Preferred shares issued as compensation	63,000	0	2,711,241
Common shares and warrants issued for services	64,500	47,000	3,625,577
Common shares issued for interest	'	0	665,497
Warrants granted to scientific advisory board	137,602	75,000	1,344,440
Amortization of deferred compensation	0	0	121,424
Depreciation	106,072	105,438	1,142,824
Amortization	4,387	4,388	46,307
Change in fair value of derivative liability	3,826,274	226,549	5,117,146
Amortization of deferred financing expenses	0	0	51,175
Discount convertible debentures	276,254	0	350,184
Beneficial conversion feature of convertible debentures	0	0	713,079
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses	-208,011	-487,415	-798,391
Other current assets	0	0	-8,001
Deferred expenses	0	0	-2,175
Accounts payable - trade	-18,978	47,954	588,660
Accounts payable - related parties	176,025	301,203	886,592
Accrued expenses	20,531	-25,390	224,888
NET CASH USED IN OPERATING ACTIVITIES	-3,517,506	-2,717,613	-29,477,479
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Security deposit	-1,000,000	0	-2,000,000
Purchase of property and equipment	-2,357,983	0	-3,863,631
Purchase of trademark	0	0	-458,955
NET CASH USED IN INVESTING ACTIVITIES	-3,357,983	0	-6,322,586
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Debentures	0	'	6,000,000
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs	9,690,450	0	20,987,198
Proceeds from exercise of stock options	0	0	90,000
Proceeds from exercise of warrants	210,626	0	3,373,216
Collection of stock subscriptions received	0	0	20
NET CASH PROVIDED BY FINANCING ACTIVITIES	9,901,076	2,322,500	52,748,897
NET CHANGE IN CASH	3,025,587	-395,083	16,948,832
Cash at beginning of period	13,923,245	14,274,985	0
Cash at end of period	16,948,832	13,879,902	16,948,832
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:	'	'	'
Interest paid	0	0	0
Income tax paid	0	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued for services rendered	64,500	47,000	12,043,302
Preferred stock issued as compensation	63,000	0	3,684,782
Stock options issued to the officers as compensation	0	0	121,424
Stock warrants granted to scientific advisory board	137,602	75,000	1,202,840
Stock warrants granted to brokers	113,696	0	117,259
Common stock issued for interest on debentures	0	0	73,930
Shares of common stock issued in connection with debenture offering	0	0	49,000
Common stock issued upon conversion of convertible debentures	0	0	1,000,000
Common stock issued for dividends onPreferred Stock	'	57,486	234,508
Debt discount related to beneficial conversion feature of convertible debt	0	0	713,079
Stock Warrants issued in connection with Private Placement	0	0	7,681,578
Common stock issued for accounts payable	0	0	175,020
Common stock issued for equipment	0	0	137,500
Series B Convertible Preferred Stock [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Preferred stock, net	0	0	19,462,500
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued upon conversion of Preferred Stock	0	'	20,320,630
Series C Convertible Preferred Stock [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Preferred stock, net	0	2,322,500	2,835,963
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued upon conversion of Preferred Stock	'	$5,098,189	$5,396,661

Organization_and_Nature_of_Bus

Organization and Nature of Business	6 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 – Organization and Nature of Business
	NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. and which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.
	On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.
	Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 newly issued shares of ECMM common stock resulting in an aggregate of 100,000,000 shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of 4,000 shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.
	As a result of the Exchange transaction, the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.
	On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  The Company is considered a development stage company at this time.
	NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a development stage company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour Pharma on  September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.
	On February 15, 2010 the Company executed an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”).  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The 2,000,000 shares were valued at the par value of $2,000(adjusted for the reverse split).
	We focus our research and clinical programs on specific anti-viral therapeutics. The Company’s platform technology is based on novel biomimetic nanomedicine constructs, called nanoviricides®. A nanoviricide isdesigned to “fool” the virus into binding to the nanoviricide in the same fashion that it would bind to the host cell. Because the host cell receptor and how the virus binds to it does not change despite all the changes in the virus, the Company believes that our broad-spectrum nanoviricides should continue to work against the virus despite the viral mutations and other changes. We are seeking to add to our existing portfolio of products through our internal discovery and clinical development programs and through an in-licensing strategy.
	The Company has held a pre-IND Meeting with the US FDA for its clinical drug candidate NV-INF-1 in the FluCide™ program. The Company is developing this injectable drug (NV-INF-1) for hospitalized patients with severe influenza, including immuno-compromised patients. The Company believes that this drug may also be usable as a single-dose injection in a medical office for less severe cases of influenza. The Company has also developed an oral anti-influenza drug candidate, NV-INF-2, with a very high degree of effectiveness when taken by mouth. This may be the first ever nanomedicine that is orally active. Both of these anti-influenza therapeutic candidates are “broad-spectrum”, i.e. they are expected to be effective against most if not all types of influenzas including Bird Flu H5N1, Highly Pathogenic Influenzas (HPI/HPAI), Epidemic Influenzas such as the 2009 “swine flu” H1N1/A/2009, and Seasonal Influenzas including the recent H3N2 influenza. The Company has already demonstrated that they have significantly superior activity when compared to oseltamivir (Tamiflu®) against two unrelated influenza A subtypes, namely, H1N1 and H3N2 in a highly lethal animal model. Both of these drug candidates can be used as prophylactics to protect at-risk personnel such as health-care workers and immediate family members and caretakers of a patient.
	The Company’s broad-spectrum drug candidate for the treatment of dengue viral infections, DengueCide™, has received “orphan drug” status from both the US FDA and the European Medicines Agency (“EMA”). This orphan drug status carries with it several tax benefits and other financial equivalent incentives. Notably, in the US, orphan drug status will enable us to gain a “Priority Review Voucher” that can be applied to another drug development program or can be sold for a consideration to another pharmaceutical company, once the drug is approved. The Company has therefore prioritized its Dengue drug development program.
	The Company is also developing an anti-HIV drug. The drug candidates in this HIVCide(™) program were found to have effectiveness equal to that of a triple drug HAART cocktail therapy in the standard humanized SCID-hu Thy/Liv mouse model. Moreover, the nanoviricides were long acting. Viral load suppression continued to hold for more than four weeks after stopping HIVCide treatment. The Company believes that the strong effect and sustained effect indicate that an HIVCide can be developed as a single agent that would provide “Functional Cure”from HIV/AIDS. The Company believes that substantially all HIV virus can be cleared upon HIVCide treatment, except the integrated viral genome in latent cells. This would enable discontinuation of treatment until HIV reemerges from the latent reservoir, which may be several months without any drugs. Moreover, the Company believes that the this therapy would also minimize the chances of HIV transmission. The Company is currently optimizing the anti-HIV drug candidates. These drug candidates are effective against both the R5 and X4 subtypes of HIV-1 in cell cultures. The Company believes that these drug candidates are “broad-spectrum”, i.e. they are expected to be effective against most strains and mutants of HIV, and therefore escape of mutants from our drugs is expected to be minimal.
	The Company is also developing a broad-spectrum skin cream for the treatment of oral and genital herpesvirus infections (i.e. both HSV-1 and HSV-2).
	In addition, the Company is also developing broad-spectrum eye drops that are expected to be effective against a majority of the viral infections of the external eye. Most of these viral infections are from adenoviruses or from herpesviruses. The Company has shown excellent efficacy of its drug candidates against EKC (adenoviral epidemic kerato-conjunctivitis) in an animal model. In addition, the anti-HSV drug candidates have shown excellent efficacy in cell culture studies. The Company is also developing a skin cream formulation for the treatment of herpes cold sores or genital warts. Further, the Company is also developing a broad-spectrum drug against Dengue viruses that is expected to be useful for the treatment of any of the four major serotypes of dengue viruses, including in severe cases of dengue (DSS) and dengue hemorrhagic fever (DHF). DSS and DHF are thought to be caused by prior antibodies against dengue that a patient’s body creates to fight a second unrelated dengue infection, and the second virus uses these antibodies effectively to hitch a ride into human cells, thereby causing a more severe infection than in naive patients. In addition to these six drugs in development, the Company also has research programs against Rabies virus, Ebola and Marburg viruses, and others. To date, the Company does not have any commercialized products.
	Thus, at present, the Company has six drug programs in its pipeline that have shown significant successes in cell culture as well as animal models. The Company’s platform technology enables rapid development of drug candidates against novel infections. The Company believes that it will continue to expand its pipeline as available funds and opportunities permit.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2 – Summary of Significant Accounting Policies
	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K for the fiscal year ended June 30, 2013 filed with the SEC on September 30, 2013.
	For a summary of significant accounting policies (which have not changed from June 30, 2013), see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013.
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the		For the Fiscal
		Six Months		Year
		Ended		Ended
		31-Dec-13		30-Jun-13
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance		535,715		535,715
	Sub-total: stock options		535,715		535,715
	Warrants
	Warrants issued from June 15, 2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		513,143		513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		466,486		466,486
	Warrants issued from June 15, 2008 through May 15 ,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2014		211,429		211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		561,628		568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		1,437,871		1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015		65,714		65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016		68,571		68,571
	Warrants issued from August 16, 2012 to May 15, 2013 to SAB for services with an exercise price ranging from $1.89 to $5.88 per share expiring fiscal year ending June 30, 2017		68,571		68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring February 28, 2018 less Warrants exercised on September 25, 2013		2,910,071		-
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017		21,000		-
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring February,28, 2018		58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017		17,143		-
	Sub-total: warrants		6,400,537		3,400,556
	Total potentially outstanding dilutive common shares		6,936,251		3,929,127
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At December 31, 2013 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,237,113 based upon the Selling price of the Company’s common stock on December 31, 2013. At December 31, 2013 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,714,286.
	Recently Issued Accounting Pronouncements
	In February 2013, the FASB issued ASU No. 2013-02, "Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other ComprehensiveIncome." The ASUadds new disclosure requirements for items reclassified out of accumulated other comprehensive income by component and their corresponding effect on net income. The ASU is effective for public entities for fiscal years beginning after December 15, 2013.
	In February 2013, the Financial Accounting Standards Board, or FASB, issued ASU No. 2013-04, "Liabilities (Topic 405): Obligations Resulting from Joint andSeveral Liability Arrangements for which the Total Amount of the Obligation Is Fixed at the Reporting Date." This ASU addresses the recognition, measurement, and disclosure of certain obligations resulting from joint and several arrangements including debt arrangements, other contractual obligations, and settled litigation and judicial rulings. The ASU is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	In March 2013, the FASB issued ASU No. 2013-05, "Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity." This ASU addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income and is intended by FASB to eliminate some disparity in current accounting practice. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	In March 2013, the FASB issued ASU 2013-07,“Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting.” The amendments require an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent. Liquidation is imminent when the likelihood is remote that the entity will return from liquidation and either (a) a plan for liquidation is approved by the person or persons with the authority to make such a plan effective and the likelihood is remote that the execution of the plan will be blocked by other parties or (b) a plan for liquidation is being imposed by other forces (for example, involuntary bankruptcy). If a plan for liquidation was specified in the entity’s governing documents from the entity’s inception (for example, limited-life entities), the entity should apply the liquidation basis of accounting only if the approved plan for liquidation differs from the plan for liquidation that was specified at the entity’s inception. The amendments require financial statements prepared using the liquidation basis of accounting to present relevant information about an entity’s expected resources in liquidation by measuring and presenting assets at the amount of the expected cash proceeds from liquidation. The entity should include in its presentation of assets any items it had not previously recognized under U.S. GAAP but that it expects to either sell in liquidation or use in settling liabilities (for example, trademarks). The amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Financial_Condition

Financial Condition	6 Months Ended
	Dec. 31, 2013
Financial Conditons Disclosure [Abstract]	'
Financial Conditons Disclosure [Text Block]	'
	Note 3 – Financial Condition
	The Company’s financial statements for the interim period ended December 31, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business.  The Company has a deficit accumulated during the development stage.  In addition, the Company has not generated any revenues and no revenues are anticipated in the short-term.  Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs.  The Company has not yet commenced any product commercialization.  Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of December 31, 2013 the Company had cash and cash equivalents of $16,948,832. In addition, subsequent to this time-period, on January 21, 2014, the Company has raised an additional approximately $20 Million in a registered direct offering through a sale of units comprising its common stock and warrants (See below). The Company has sufficient capital to continue its business, at least, through December 31, 2015, at the current rate of expenditure. The Company therefore would not be considered to have risks relative to its ability to continue as a going concern within the applicable guidelines.
	While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities.
	On February 1, 2013 the Company consummated an offering (the “Offering”) in the aggregate amount of $6,000,000 for its Unsecured 8% Coupon Series B Convertible Debenture (the “Debentures”) to four equity investors comprised of private, family investment offices and a charitable foundation. The Debentures are due on January 31, 2017 (the “Maturity Date”) and are convertible into restricted shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) at the market price per share of Common Stock on the date of convergence.
	On September 9, 2013, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $3.50 (“Purchase Price”) per Unit, consisting of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $5.25 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”) The Warrants are exercisable immediately and expire five years after issuance. On September 12, 2013, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”), and the Company raised gross proceeds of $10,308,996 before Offering costs of approximately $618,540, which includes placement agent and attorneys’ fees. On September 25, 2013 certain of the warrant holders exercised Warrants to purchase 35,357 shares of common stock at $5.25 per share for a total exercise price of $185,624.25.
	Subsequent to the reporting period, on January 21, 2014, the Registrant entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $5.25 (“Purchase Price”) per Unit. The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Registrant’s stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Registrant’s stock on Friday, January 17, 2014.  Each Unit consisted of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $6.05 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”). The Warrants are exercisable immediately and expire five years after issuance. On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) of 3,815,285 shares of Common Stock and 2,479,935 Warrants, and the Company raised gross proceeds of $20,030,246.25 before estimated expenses of the Offering of approximately $1,200,000, which includes placement agent fees but does not include and attorneys’ fees and other expenses.
	As a result of the successful sale of the Company’s Common Shares, management believes that the Company has sufficient cash and cash equivalents to meet its budgeted expenditures through, at least, December 31, 2015 at current rate of expenditures.
	Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral nanomedicines.  The Company has not yet commenced any product commercialization.  The Company has incurred significant losses from operations since its inception, resulting in a deficit accumulated during the development stage of $46,264,945 at December 31, 2013 and expects recurring losses from operations to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations.  There can be no assurance that the Company will achieve or maintain profitability in the future.  Despite the Company’s financings in 2014 and 2013 and a cash and cash equivalent balance of $16,948,832 at December 31, 2013, substantial additional financing will be required in future periods.  The Company may require additional capital to finance planned and currently unplanned capital costs, and additional staffing requirements during the next twenty four months.  The Company has, in the past, adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its Plan of Operations as necessary, if it is unable to raise such additional funds.

Significant_Alliances_and_Rela

Significant Alliances and Related Parties	6 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 4 – Significant Alliances and Related Parties
	TheraCour Pharma, Inc.
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.  In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (4) make royalty payments (calculated as a percentage of net sales of the licensed drugs) of 15% to TheraCour Pharma, Inc. and (5) agreed that TheraCour Pharma, Inc. retains the exclusive right to develop and manufacture the licensed drugs. TheraCour Pharma, Inc. agreed that it will manufacture the licensed drugs exclusively for NanoViricides, and unless such license is terminated, will not manufacture such product for its own sake or for others.
	On February 15, 2010, the Company executed an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”).  Pursuant to the exclusive Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies developed by TheraCour for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to seven million shares of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends; have no liquidation preference and are not to be amended without the holders approval. The issuance of the 2,000,000 shares was valued at their par value or $2,000.
	TheraCour Pharma, Inc. may terminate these licenses upon a material breach by us as specified in the agreement.
	Development costs charged by and paid to TheraCour were $1,411,327 and $1,088,484 for the Six months ended December 31, 2013, and 2012, respectively and $9,116,815 since inception. As of December 31, 2013, pursuant to its license agreement, the Company has paid a security advance of $795,715 to and held by TheraCour which is reflected in Prepaid Expenses.  No royalties are due TheraCour from the Company’s inception through December 31, 2013.
	Anil R. Diwan, President, and a director of the Company, is also a Director and President of TheraCour. Dr. Diwan owns approximately 70% of the common stock of TheraCour, which itself owns approximately 19% of the Common stock of the Company.
	TheraCour owns approximatelys 9,476,000 shares of the Company’s outstanding common stock as of December 31, 2013.
	KARD Scientific, Inc.
	In June 2005, the Company engaged KARD Scientific to conduct preclinical animal studies and provide the Company with a full history of the study and final report with the data collected from Good Laboratory Practices (CGLP) style studies. Dr. Krishna Menon, the Company’s Consulting Chief Regulatory Officer, a non-executive position, is also an officer and principal owner of KARD Scientific. Lab fees charged by KARD Scientific for services for the six months ended December 31, 2013, and 2012, were $314,155 and $561,618 respectively.
	KARD Scientific Inc. of Beverly, Massachusetts, is currently our primary vendor for animal model study design and performance. KARD operates its own facilities in Beverly, Massachusetts.
	NanoViricides has a fee for service arrangement with KARD. We do not have an exclusive arrangement with KARD; we do not have a contract with KARD; any work to be performed by KARD must be commissioned by the executive officers of NanoViricides; and we retain all intellectual property resulting from the services by KARD.

Prepaid_Expenses

Prepaid Expenses	6 Months Ended
	Dec. 31, 2013
Prepaid Expenses [Abstract]	'
Prepaid Expenses Disclosure [Text Block]	'
	Note 5 - Prepaid Expenses
	Prepaid Expenses are summarized as follows:
		December 31,		June 30,
		2013		2013
	TheraCour Pharma, Inc.	$	795,715	$	546,783
	Prepaid Others		10.676		51,597
		$	806,391	$	598,380

Equity_Transactions

Equity Transactions	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6 – Equity Transactions
	In accordance with the Registrant’s reverse stock split on a 1 for 3.5 basis, effective September 10, 2013, the Registrant filed a Certificate of Change to its Articles of Incorporation pursuant to Section 78.209 of the Nevada Revised Statutes (the “Amendment”) on September 3, 2013. The Amendment effectuated a reverse stock split of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) by simultaneously decreasing the number of the Registrant’s authorized and outstanding capital stock on a basis of 1 for 3.5 shares (the “Split”). Accordingly, upon effectiveness of the Split, the Registrant’s authorized capital stock shall consist of (i) 85,714,286 shares of Common Stock and (ii) 5,714,286 blank check preferred shares, par value $0.001 (the “Preferred Stock”), of which approximately 50,028,701 shares of Common Stock and 2,990,000 shares of Preferred Stock were outstanding. All share amounts and per share amounts have been restated to reflect this reverse stock split. In conjunction with the reverse stock split, the Company’s Board of Directors authorized the issuance of 5,940 shares of the Company’s common stock to round up fractional shares resulting from the reverse stock split.
	The Registrant elected to effectuate the Reserve Split in order that the price of the Common Stock qualify for listing on a national securities exchange. The Amendment was unanimously approved by the Board of Directors so that the Common Stock would comply with such listing requirement
	On September 9, 2013, NanoViricides Inc. entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $3.50 (“Purchase Price”) per Unit, consisting of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $5.25 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”) The Warrants are exercisable immediately and expire five years after issuance.
	On September 12, 2013, post reserve -split the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”), and the Company raised gross proceeds of $10,308,996 before estimated expenses of the Offering of approximately $618,540, which includes placement agent and attorneys’ fees. The Company issued 2,945,428 Units. On September 25, 2013 certain of these Unit Holders exercised 35,357 Warrants to purchase 35,357 shares of the Company’s common stock, par value $0.001 per share, for gross proceeds of $185,624.
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		9-Sep-13
	Expected life (year)		5
	Expected volatility		78.39	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		1.39	%
	The estimated relative fair value of the warrants issued in conjunction with the aforesaid offering was $4,068,343 at the date of issuance using the Black-Scholes Option Pricing Model.
	The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange Commission a prospectus supplement relating to the Offering.
	In connection with the Offering, pursuant to a Placement Agency Agreement dated September 9, 2013 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”), the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the “Compensation Warrants”) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share. The Compensation Warrants will otherwise comply with FINRA Rule 5110(g)(1) in that for a period of six months after the issuance date of the Compensation Warrants, neither the Compensation Warrants nor any warrant shares issued upon exercise of the compensation warrants shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Closing. Upon issuance of the commission warrants , the company recognized Costs associated with the sale of securities ( a capital item ) of $113,696 and a corresponding increase in additional paid in capital of $113,696.
	On September 25, 2013, the Company’s Common Stock began trading on the NYSE MKTexchange.
	Unregistered Securities
	In August, 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 21,000 shares of common stock at $5.17 per share expiring in August ,2017.  These warrants were valued at $106,050 and recorded as consulting expense.
	In September, 2013, the Company’s Board of Directors authorized the issuance of Warrants to Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”) to purchase a total of 58,910 shares of common stock at $5.25 per share expiring in September, 2018.  These warrants were valued at $113,696 and recorded as Placement Agents Fees related to the sale of Common Shares and Warrants on September 10, 2013.
	For the three months ended September 30, 2013, the Company's Board of Directors authorized the issuance of 10,311 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $21,000.
	For the three months ended September 30, 2013, the Company's Board of Directors authorized the issuance of 5,501 shares of its common stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
	In October, 2013 the Board of Directors authorized the issuance of 5,117 shares of the Company’s $0.001 Par Value Series A Convertible Preferred Stock as employee compensation and recognized an expense of $35,995.
	In November, 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $6.56 per share expiring in November ,2017.  These warrants were valued at $31,552 and recorded as consulting expense.
	In December, 2013, the Company issued 7,143 shares of the Company’s $0.001 par value Common Stock with a restrictive legend at $3.50 per share upon the exercise of Warrants.
	For the three months ended December 31, 2013, the Company's Board of Directors authorized the issuance of 4,069 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $21,000.
	In December, 2013 the Board of Directors authorized the issuance of 1,495 shares of the Company’s $0.001 Par Value Series A Convertible Preferred Stock as employee compensation and recognized an expense of $26,998.
	For the three months ended December 31, 2013, the Company's Board of Directors authorized the issuance of 2,220 shares of its common stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.

Stock_Options_and_Warrants

Stock Options and Warrants	6 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 7 - Stock Options and Warrants
	Stock Options
	In September 2005, 500,000 stock options were granted to Eugene Seymour, our CEO under an employment agreement.  Of these options, 250,000 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining  options vested annually on January 1, 2007 and 2008 in two  equal amounts.
	In September 2005, 1,000,000 stock options were granted to Anil Diwan, our Chairman and President under an employment agreement.  Of these options, 333,333 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining options vested annually on January 1, 2007 and January 1, 2008 in two equal amounts.
	In September 2005, 500,000 stock options were granted to Leo Ehrlich, our former CFO under an employment agreement. Of these options, 250,000 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining options vest annually in two equal amounts.   On May 16, 2007, Leo Ehrlich resigned as the Company's Chief Financial Officer. At time of his resignation 375,000 options were vested and are exercisable from September 2005 until September 2015.The remaining options were forfeited.
	The Company has accounted for these options granted to officers under the provisions of paragraph 718-10-30 of the FASB Accounting Standards Codification.” Based on fair market value of these options, $7,044 was recognized as stock based compensation expense for the years ended June 30, 2009.  For the year ended June 30, 2010 and 2011, the Company did not record any compensation expense related to these options.
	The following table presents the combined activity of stock options issued for the years ended June 30, as follows:
	Stock Options	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise Price		Remaining		($)
				per share ($)		Contractual Term
						(years)
	Outstanding at June 30, 2013		535,715		0.1		2.23		850,000
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Canceled		-		-		-		-
	Outstanding at December 31,2013		535,715		-		-		1,827,433
	As of December 31, 2013 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise		Remaining		($)
				Price		Contractual Term
				per share ($)		(years)
	Outstanding at June 30, 2013		3,400,556						-
	Granted		3,042,480		4.58		2.99		-
	Exercised		42,499		-		-		-
	Expired				-		-		-
	Canceled		-		-		-		-
	Outstanding at December 31,2013		6,400,537		4.66		2.53		3,928,098
	Of the above warrants, 3,190,557 expire in fiscal year ending June 30, 2014; 65,714 expire in fiscal year ending June 30, 2015; and 68,571 expire in fiscal year ended June 30, 2016; 68,571 expire in fiscal year ending June 30, 2017; 3,007,124 expire in fiscal year ending June 30, 2018.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 8 - Commitments and Contingencies
	Operating Lease
	The Company’s principal executive offices are located at 135 Wood Street, West Haven, Connecticut, and include approximately 7,000 square feet of office and laboratory space at a base monthly rent of $8,695. The term of lease expired on February 28, 2011 and is now on a month-by-month basis.
	Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $52,170 and $52,170 for the six months ended December 31, 2013 and 2012, respectively.
	On February 11, 2013, the Company entered into a binding Memorandum of Understanding (“MOU”) with Inno-Haven, LLC, a Connecticut Limited Liability Company (“Inno-Haven”), to lease for a four-year term a 18,000 square foot building located at 1 Controls Drive, Shelton, Connecticut (the “Leased Premises”) to be suitable for laboratory and GMP clean room drug manufacturing. Inno-Haven is controlled by Anil Diwan, the Company’s founder, President and Chairman and controlling shareholder of TheraCour Pharma, Inc., the Company’s principal shareholder (“TheraCour”). The MOU is subject to a definitive lease agreement (the “Lease Agreement”) to be executed upon final determination of the cost of the laboratory and GMP clean room, and which would contain definitive terms regarding rent, taxes, utilities, maintenance and other, similar items. Pursuant to the MOU, the Company has agreed to provide up to $2,000,000 in cash collateral for sums borrowed by Inno-Haven (collectively, the “Loans”) to complete the build-out and renovation of the Leased Premises for the benefit of the Company. The Company agreed to file a registration statement for shares of its restricted Common Stock, provided by TheraCour Pharma, Inc., as additional collateral for any or all of the Loans (the “Registrable Shares”). The Company shall file a registration statement within ninety (90) days of a closing of a Loan (a “Closing”) to cover such Registrable Shares and use its best efforts to have such registration statement declared effective no later than one hundred eighty (180) days following the Closing, and keep such registration statement effective until the termination of the respective collateral agreement upon request to do so by Inno-Haven. The MOU further provides that, so long as there is no breach of the Lease Agreement by the Company, any distribution of the collateral in accordance with a Loan will first be made from the proceeds of life insurance policies (if applicable), then from the proceeds of the sale of the Registrable Shares, and then, should there be any balance still owing to the lender, from the cash collateral.
	Also on February 11, 2013, pursuant to the provisions of the MOU, the Company transferred $1,000,000 as cash collateral (the “Cash Collateral”) and agreed to register a number of shares of the Company’s Common Stock, which shares were provided by TheraCour Pharma, Inc., equal to $1,000,000 (the “Collateral Shares”) as collateral pursuant to a Loan and Security Agreement entered into between Inno-Haven and a non-affiliated lender (the “Loan Agreement”) for a loan in the principal amount of $2,000,000. On September 17, 2013 The Company transferred the remaining $1,000,000 cash collateral to Inno-Haven. The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares. Moreover, Inno-Haven is required to obtain a life insurance policy to insure the life of Dr. Diwan in the amount of $2,000,000. If Dr. Diwan dies during the term of the Loan Agreement, the lender shall have the option to demand payment of the balance of the loan, but, shall be repaid first from the proceeds of any life insurance policy (if applicable), then from the proceeds of the sale of the Collateral Shares, and then, should there be any balance still owing to the lender, from the Cash Collateral. As of December 31, 2013 the Company has utilized approximately $1.1 million for specific fixtures and improvements it required for the new labaratory and cGMP facilities.
	Total rent expense paid to Inno-Haven during this period amounted to $-0- for the six months ended December 31, 2013 and $-0- since February 11, 2013.
	Legal Proceedings
	On or around January 18, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-654437-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”).  The Complaint seeks to compel inspection of the Company’s books and records.  On or about February 14, 2012 we filed a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted.  The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which it is not entitled.  The Complaint by a holder of less than 1 percent of the common stock of the Company seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute.  Management believes that this lawsuit has no merit or basis and intends to vigorously defend it.  Monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation. On April 9, 2012, the Court dismissed the Complaint for failure to state a Claim for which relief could be granted.
	On or about April 13, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-659535-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”). The Complaint seeks to compel inspection of the Company’s books and records. On or about May 2, 2012, the Company filed a Demand for Security of Costs. Upon filing of the Demand, proceedings relative to the Company are stayed pending posting of the demanded security (or plaintiff engages in motion practice about the Demand). The Company may seek dismissal of the complaint if plaintiff has not posted the demanded security (or engaged the court). The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which the Company believes it is not entitled. The Complaint, by a holder of less than 1 percent of the common stock of the Company, seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute. On or about July 18, 2012, the Plaintiff moved to amend its answer. On or about August 8, 2012, we filed our opposition to Plaintiff’s Motion to Amend and a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted. On or about September 13, 2012 the court granted the Plaintiff’s Motion to Amend. On or about September 17, 2012 the Plaintiff served its “Second Amended Shareholder Derivative Complaint” upon our Counsel in Nevada. As in the prior two complaints that this Plaintiff has filed in this action, the Second Amended Complaint sought to compel inspection of the Company’s books and records, sought injunctive relief, an accounting and alleges breach of Fiduciary by Dr. Seymour and Dr. Diwan. On or about October 11, 2012, we filed a Motion to Dismiss the Second Amended Complaint for failure to state a claim upon which relief can be granted. On or about December 4, 2012, the Court granted the Company’s Motion to Dismiss with respect to Dr. Seymour and Dr. Diwan and ordered the case dismissed as to all claims but the Plaintiff’s request to compel documents required to be maintained by the Company’s registered agent in Nevada pursuant to NRS 78.105. On or about December 26, 2012, the Company provided the Plaintiff with each of the documents to which it is entitled. Management believes that the Plaintiff does not have a legal or good faith basis for inspection or copying of its shareholder’s list and intends to vigorously defend the production thereof. In May, 2013, the Plaintiff filed a motion for permission to file a third amended complaint. The Company subsequently filed a motion to dismiss and for Summary Judgment. The Court denied the Motion to Dismiss and for Summary Judgment and ordered the Plaintiff to file its Third Amended Complaint. On or about July 15, 2013 the Company Petitioned the Nevada Supreme Court for a Writ of Prohibition or Mandamus reversing the trial Court’s denial of Summary Judgment. Thereafter, on or about September 20, 2013, the Nevada Supreme Court denied the Company’s Writ Petition. The Company filed its answer to the Third Amended Complaint, which contains only one cause of action which is identical to the sole cause of action which was not dismissed from the Second Amended Complaint. Specifically, the Third Amended Complaint seeks only to compel production of books and records required to be maintained by the Company’s Registered Agent pursuant to NRS 78.105 Management believes that the Company’s registered Agent has provided the Plaintiff with all documents to which it is entitled pursuant to NRS 78.105 and that this lawsuit has no merit or basis. The Company intends to vigorously defend this lawsuit. Specific monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation.
	On or about July 15, 2013 the same Plaintiff that had filed the repetitive complaints in the Nevada action as set forth in the preceding paragraphs (Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc.) filed a Shareholder Derivative complaint with the United States District Court for the District of Colorado .  The Plaintiff asserts the action is a shareholder derivative action and the Company is solely a nominal defendant.  The Company maintains that it, as well as the individual defendants, Messrs. Seymour and Diwan, have not been served in the action. However, a default was filed against the Company, which has been vacated. The Complaint alleges that the Company has failed to deliver information requested by the Plaintiff, the identical information the Plaintiff is seeking inspection of in the Nevada action, and that the individual defendants, Messrs. Seymour and Diwan, breached their fiduciary duties to the Company and caused it financial harm.  The Plaintiff demands an order to inspect the Company’s records, an order revoking Messrs. Diwan and Seymour from the Board of Directors, equitable relief, and consequential and punitive damages.  The Company believes these claims have no merit and the Company intends to defend this action vigorously. The Company has moved the District Court to dismiss the action in its entirety Though consequential and punitive damages are claimed, no facts have been submitted to support such claim. Management has determined that such claims are specious and not relevant to the Company and no accrual has been made in relation to this litigation.
	There are no other legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.

Subsequent_Events

Subsequent Events	6 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 9 – Subsequent Events
	Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The Management of the Company has determined that there was a reportable subsequent event to be disclosed as follows:
	On January 21, 2014, the Registrant entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $5.25 (“Purchase Price”) per Unit. The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Registrant’s stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Registrant’s stock on Friday, January 17, 2014.  Each Unit consisted of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $6.05 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”). The Warrants are exercisable immediately and expire five years after issuance. On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) of 3,815,285 shares of Common Stock and 2,479,935 Warrants, and the Company raised gross proceeds of $20,030,246.25 before estimated expenses of the Offering of approximately $1,200,000, which includes placement agent fees but does not include and attorneys’ fees and other expenses.
	On January 22, 2014, a Warrant Holder exercised 75,000 warrants at a per share price of $5.25, and received 75,000 shares of the Company’s $0.001 par value common stock at an aggregate purchase price of $393,750.00.
	On February 6, 2014, a Warrant Holder exercised 25,000 warrants at a per share price of $5.25, and received 25,000 shares of the Company’s $0.001 par value common stock at an aggregate purchase price of $131,250.00.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K for the fiscal year ended June 30, 2013 filed with the SEC on September 30, 2013.
	For a summary of significant accounting policies (which have not changed from June 30, 2013), see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the		For the Fiscal
		Six Months		Year
		Ended		Ended
		31-Dec-13		30-Jun-13
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance		535,715		535,715
	Sub-total: stock options		535,715		535,715
	Warrants
	Warrants issued from June 15, 2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		513,143		513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		466,486		466,486
	Warrants issued from June 15, 2008 through May 15 ,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2014		211,429		211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		561,628		568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		1,437,871		1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015		65,714		65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016		68,571		68,571
	Warrants issued from August 16, 2012 to May 15, 2013 to SAB for services with an exercise price ranging from $1.89 to $5.88 per share expiring fiscal year ending June 30, 2017		68,571		68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring February 28, 2018 less Warrants exercised on September 25, 2013		2,910,071		-
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017		21,000		-
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring February,28, 2018		58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017		17,143		-
	Sub-total: warrants		6,400,537		3,400,556
	Total potentially outstanding dilutive common shares		6,936,251		3,929,127
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At December 31, 2013 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,237,113 based upon the Selling price of the Company’s common stock on December 31, 2013. At December 31, 2013 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,714,286.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	In February 2013, the FASB issued ASU No. 2013-02, "Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other ComprehensiveIncome." The ASUadds new disclosure requirements for items reclassified out of accumulated other comprehensive income by component and their corresponding effect on net income. The ASU is effective for public entities for fiscal years beginning after December 15, 2013.
	In February 2013, the Financial Accounting Standards Board, or FASB, issued ASU No. 2013-04, "Liabilities (Topic 405): Obligations Resulting from Joint andSeveral Liability Arrangements for which the Total Amount of the Obligation Is Fixed at the Reporting Date." This ASU addresses the recognition, measurement, and disclosure of certain obligations resulting from joint and several arrangements including debt arrangements, other contractual obligations, and settled litigation and judicial rulings. The ASU is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	In March 2013, the FASB issued ASU No. 2013-05, "Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity." This ASU addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income and is intended by FASB to eliminate some disparity in current accounting practice. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	In March 2013, the FASB issued ASU 2013-07,“Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting.” The amendments require an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent. Liquidation is imminent when the likelihood is remote that the entity will return from liquidation and either (a) a plan for liquidation is approved by the person or persons with the authority to make such a plan effective and the likelihood is remote that the execution of the plan will be blocked by other parties or (b) a plan for liquidation is being imposed by other forces (for example, involuntary bankruptcy). If a plan for liquidation was specified in the entity’s governing documents from the entity’s inception (for example, limited-life entities), the entity should apply the liquidation basis of accounting only if the approved plan for liquidation differs from the plan for liquidation that was specified at the entity’s inception. The amendments require financial statements prepared using the liquidation basis of accounting to present relevant information about an entity’s expected resources in liquidation by measuring and presenting assets at the amount of the expected cash proceeds from liquidation. The entity should include in its presentation of assets any items it had not previously recognized under U.S. GAAP but that it expects to either sell in liquidation or use in settling liabilities (for example, trademarks). The amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the		For the Fiscal
		Six Months		Year
		Ended		Ended
		31-Dec-13		30-Jun-13
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance		535,715		535,715
	Sub-total: stock options		535,715		535,715
	Warrants
	Warrants issued from June 15, 2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		513,143		513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28, 2014		466,486		466,486
	Warrants issued from June 15, 2008 through May 15 ,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2014		211,429		211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		561,628		568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		1,437,871		1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015		65,714		65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016		68,571		68,571
	Warrants issued from August 16, 2012 to May 15, 2013 to SAB for services with an exercise price ranging from $1.89 to $5.88 per share expiring fiscal year ending June 30, 2017		68,571		68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring February 28, 2018 less Warrants exercised on September 25, 2013		2,910,071		-
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017		21,000		-
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring February,28, 2018		58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017		17,143		-
	Sub-total: warrants		6,400,537		3,400,556
	Total potentially outstanding dilutive common shares		6,936,251		3,929,127

Prepaid_Expenses_Tables

Prepaid Expenses (Tables)	6 Months Ended
	Dec. 31, 2013
Prepaid Expenses [Abstract]	'
Schedule Of Prepaid Expenses [Table Text Block]	'
	Prepaid Expenses are summarized as follows:
		December 31,		June 30,
		2013		2013
	TheraCour Pharma, Inc.	$	795,715	$	546,783
	Prepaid Others		10.676		51,597
		$	806,391	$	598,380

Equity_Transactions_Tables

Equity Transactions (Tables)	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		9-Sep-13
	Expected life (year)		5
	Expected volatility		78.39	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		1.39	%

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	6 Months Ended
	Dec. 31, 2013
Equity Option [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table presents the combined activity of stock options issued for the years ended June 30, as follows:
	Stock Options	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise Price		Remaining		($)
				per share ($)		Contractual Term
						(years)
	Outstanding at June 30, 2013		535,715		0.1		2.23		850,000
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Canceled		-		-		-		-
	Outstanding at December 31,2013		535,715		-		-		1,827,433
Stock Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise		Remaining		($)
				Price		Contractual Term
				per share ($)		(years)
	Outstanding at June 30, 2013		3,400,556						-
	Granted		3,042,480		4.58		2.99		-
	Exercised		42,499		-		-		-
	Expired				-		-		-
	Canceled		-		-		-		-
	Outstanding at December 31,2013		6,400,537		4.66		2.53		3,928,098

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details Textual) (USD $)	6 Months Ended		6 Months Ended	0 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Feb. 15, 2010
			ECMM [Member]	Series A Preferred Stock [Member]
Product Information [Line Items]	'	'	'	'
Entity Incorporation, State Country Name	'Colorado	'	'	'
Entity Incorporation, Date Of Incorporation	25-Jul-00	'	'	'
Business Acquisition, Name of Acquired Entity	'Edot-com.com	'	'	'
Business Acquisition, Date of Acquisition Agreement	12-May-05	'	'	'
Common Stock Shares Issued Prorata Basis	'	'	4,000	'
Common stock, shares issued	50,042,132	47,026,173	80,000,000	'
Common stock, shares, outstanding	50,042,132	47,026,173	100,000,000	'
Stockholders Equity, Reverse Stock Split	'1 for 3.5	'	'	'3.5 to 1
Business Acquisition, Percentage of Voting Interests Acquired	'	'	80.00%	'
Preferred stock, shares issued	'	'	'	2,000,000
Preferred stock	'	'	'	$2,000
Convertible Preferred Stock, Terms of Conversion	'	'	'	'The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Companys intellectual property, into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,936,251	3,929,127
Employee Stock Option [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Total Stock Option [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Warrants Issued One [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	513,143	513,143
Warrants Issued Two [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	466,486	466,486
Warrants Issued Three [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	211,429	211,429
Warrants Issued Four [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	561,628	568,771
Warrants Issued Five [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,437,871	1,437,871
Warrants Issued Six [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65,714	65,714
Warrants Issued Seven [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Eight [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Nine [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,910,071	0
Warrants Issued Ten [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,000	0
Warrants Issued Eleven [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,910	'
Warrants Issued Twelve [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	0
Total Warrants [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,400,537	3,400,556

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	1 Months Ended	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Sep. 25, 2013	Sep. 09, 2013	Jun. 30, 2013	Feb. 02, 2013
Accounting Policies [Line Items]	'	'	'	'	'	'
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Debt Conversion, Converted Instrument, Shares Issued	'	1,237,113	'	'	'	'
Debt Interest Conversion Converted Instrument Shares Issued	'	1,714,286	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$0.10	$0.10	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Expiration Term	'	'10 years	'	'	'	'
Warrants Exercise Price	$3.50	$5.25	'	'	'	'
June 15,2006 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$3.50	'	'	'	'
Warrants Expiration Date	'	28-Feb-14	'	'	'	'
August 22, 2008 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$3.50	'	'	'	'
Warrants Expiration Date	'	28-Feb-14	'	'	'	'
June 15, 2008 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Expiration Date	'	28-Feb-14	'	'	'	'
June 30, 2009 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$3.50	'	'	'	'
Warrants Expiration Date	'	28-Feb-14	'	'	'	'
September 30, 2009 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$3.50	'	'	'	'
Warrants Expiration Date	'	28-Feb-14	'	'	'	'
August 16 2010 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Expiration Date	'	30-Jun-15	'	'	'	'
August 16 2011 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Expiration Date	'	30-Jun-16	'	'	'	'
August 16 2012 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Expiration Date	'	30-Jun-17	'	'	'	'
September 10, 2013 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$5.25	'	'	'	'
Warrants Expiration Date	'	28-Feb-18	'	'	'	'
September 10, 2013 [Member] | Placement Agents [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$5.25	'	'	'	'
Warrants Expiration Date	'	28-Feb-18	'	'	'	'
August 15, 2013 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$5.17	'	'	'	'
Warrants Expiration Date	'	15-Aug-17	'	'	'	'
November 15, 2013 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$6.56	'	'	'	'
Warrants Expiration Date	'	15-Nov-17	'	'	'	'
Minimum [Member] | June 15, 2008 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$2.45	'	'	'	'
Minimum [Member] | August 16 2010 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$5.15	'	'	'	'
Minimum [Member] | August 16 2011 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$2.80	'	'	'	'
Minimum [Member] | August 16 2012 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$1.89	'	'	'	'
Maximum [Member] | June 15, 2008 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$9.38	'	'	'	'
Maximum [Member] | August 16 2010 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$6.34	'	'	'	'
Maximum [Member] | August 16 2011 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$4.94	'	'	'	'
Maximum [Member] | August 16 2012 [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Warrants Exercise Price	'	$5.88	'	'	'	'

Financial_Condition_Details_Te

Financial Condition (Details Textual) (USD $)

6 Months Ended

1 Months Ended

6 Months Ended

Dec. 31, 2013

Sep. 25, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 02, 2013

Dec. 31, 2012

Jun. 30, 2012

11-May-05

Feb. 06, 2014

Jan. 21, 2014

Jan. 22, 2014

Jan. 24, 2014

Dec. 31, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Financial Condition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

$16,948,832

'

'

$13,923,245

'

$13,879,902

$14,274,985

$0

'

'

'

'

'

Purchase Price Per Share

$5.25

'

'

'

'

'

'

'

'

$5.25

'

'

'

Purchase Price Shares

5.25

'

'

'

'

'

'

'

'

'

'

'

'

Deficit accumulated during the development stage

-46,264,946

'

'

-38,299,784

'

'

'

'

'

'

'

'

'

Unsecured Debt

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

$0.00

$0.00

$0.00

'

'

Debt Instrument, Convertible, Conversion Price

'

'

$3.50

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Initial Public Offering

10,308,996

'

'

'

'

'

'

'

131,250

'

393,750

20,030,246.25

20,030,246.25

Placement Agents and Attorneys Fees

618,540

'

'

'

'

'

'

'

'

'

'

1,200,000

'

Investment Warrants, Exercise Price

$185,624.25

'

'

'

'

'

'

'

'

'

'

'

$6.05

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

35,357

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price Unit Description

'

'

'

'

'

'

'

'

'

'The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Registrants stock price on Friday, January 17, 2014.

'

'

'

Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

2,479,935

'

Purchase And Sale Of Common Stock

'

'

'

'

'

'

'

'

'

'

'

3,815,285

'

Proceeds from Issuance of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

$20,000,000

Warrants Exercisable Period

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Significant_Alliances_and_Rela1

Significant Alliances and Related Parties (Details Textual) (USD $)	6 Months Ended		0 Months Ended	6 Months Ended		104 Months Ended	6 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Feb. 15, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			Series A Preferred Stock [Member]	Thera Cour Pharma, Inc [Member]	Thera Cour Pharma, Inc [Member]	Thera Cour Pharma, Inc [Member]	Kard Scientific Inc [Member]	Kard Scientific Inc [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'
Related Party Transaction, Description of Transaction	'charge its costs (direct and indirect) plus no more than 30% of direct costs	'	'	'	'	'	'	'
Lab Supplies and Chemicals Fees	'	'	'	$25,000	'	'	$314,155	$561,618
Other General and Administrative Expense	2,000	'	'	'	'	'	'	'
Royalty Payment Percentage Of Net Sales	15.00%	'	'	'	'	'	'	'
Preferred stock, shares issued	'	'	2,000,000	'	'	'	'	'
Preferred stock	'	'	2,000	'	'	'	'	'
Development Cost	'	'	'	1,411,327	1,088,484	9,116,815	'	'
Security Deposit	$2,000,000	$1,000,000	'	$795,715	'	$795,715	'	'
Equity Method Investment, Ownership Percentage	70.00%	'	'	19.00%	'	19.00%	'	'
Common stock, shares, outstanding	50,042,132	47,026,173	'	9,476,000	'	9,476,000	'	'
Convertable Preferred Stock Description	'	'	'As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to seven million shares of the Companys Series A Convertible Preferred Stock (the Series A Preferred Stock). The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Companys intellectual property, into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.	'	'	'	'	'

Prepaid_Expenses_Details

Prepaid Expenses (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Prepaid Expenses [Line Items]	'	'
Prepaid Others	$10.68	$51,597
Prepaid Expense	806,391	598,380
Thera Cour Pharma, Inc [Member]	'	'
Prepaid Expenses [Line Items]	'	'
Prepaid Others	$795,715	$546,783

Equity_Transactions_Details

Equity Transactions (Details)	3 Months Ended
	Sep. 30, 2013
Class of Stock [Line Items]	'
Expected life (year)	'5 years
Expected volatility	78.39%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.39%

Equity_Transactions_Details_Te

Equity Transactions (Details Textual) (USD $)

1 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Dec. 31, 2013

Nov. 30, 2013

Sep. 30, 2013

Aug. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Jun. 30, 2009

Sep. 25, 2013

Sep. 09, 2013

Sep. 03, 2013

Feb. 02, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Oct. 31, 2013

Jun. 30, 2013

Warrant [Member]

Director [Member]

Director [Member]

Director [Member]

Consulting Services [Member]

Consulting Services [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value (in dollars per share)

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

$0.00

$0.00

$0.00

Proceeds from Issuance Initial Public Offering

'

'

'

'

$10,308,996

'

'

'

'

'

'

$185,624

'

'

'

'

'

'

'

'

Placement Agents and Attorneys Fees

'

'

'

'

618,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued to a Director for services rendered (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

5,940

2,220

5,501

4,069

10,311

'

'

'

Fair Value Of Common Stock Warrant Issued During Period For Consulting Services

'

'

'

'

'

2,500

'

'

'

'

'

'

'

11,250

11,250

21,000

21,000

'

'

'

Stockholders Equity, Reverse Stock Split

'

'

'

'

'1 for 3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

$0.00

'

'

'

$0.00

$0.00

'

$0.00

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

'

17,143

'

21,000

35,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Price Per Share

'

$6.56

$5.25

$5.17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Common Stock Warrant Issued During Period For Consulting Services

'

31,552

113,696

106,050

'

'

'

'

113,696

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Period

'

'November ,2017

'September, 2018

'August ,2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued During Period Settlement Of Accounts Payable Shares

7,143

'

58,910

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,495

5,117

'

Common Stock Issued During Period Settlement Of Accounts Payable Value

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

26,998

35,995

'

Common Stock Shares Authorized After Stock Split

'

'

'

'

'

'

'

'

'

85,714,286

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

'

'

'

'

'

'

5,714,286

'

'

'

'

'

'

'

4,000,000

'

4,000,000

Common Stock Shares Outstanding After Stock Split

'

'

'

'

'

'

'

'

'

50,028,701

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

'

'

'

2,990,000

'

'

'

'

'

'

'

2,996,612

'

2,990,000

Warrants Exercise Price

$3.50

'

'

'

$5.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

2,945,428

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description Of Offering

'

'

'

'

'the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

113,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

$4,068,343

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price per share , Outstanding	$0.10	'
Equity Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding	535,715	'
Number of Shares, Granted	0	'
Number of Shares, Exercised	0	'
Number of Shares, Expired	0	'
Number of Shares, Canceled	0	'
Number of Shares, Outstanding	535,715	535,715
Weighted Average Exercise Price per share , Outstanding	$0.10	'
Weighted Average Exercise Price per share, Granted	$0	'
Weighted Average Exercise Price per share, Exercised	$0	'
Weighted Average Exercise Price per share, Expired	$0	'
Weighted Average Exercise Price per share, Canceled	$0	'
Weighted Average Exercise Price per share , Outstanding	$0	$0.10
Weighted Average Remaining Contractual Term, (year) Granted	'0 years	'
Weighted Average Remaining Contractual Term, (year) Exercised	'0 years	'
Weighted Average Remaining Contractual Term, (year) Expired	'0 years	'
Weighted Average Remaining Contractual Term, (year) Canceled	'0 years	'
Weighted Average Remaining Contractual Term, (year) Outstanding	'0 years	'2 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$850,000	'
Aggregate Intrinsic Value, Granted	0	'
Aggregate Intrinsic Value, Exercised	0	'
Aggregate Intrinsic Value, Expired	0	'
Aggregate Intrinsic Value, Canceled	0	'
Aggregate Intrinsic Value, Outstanding	$1,827,433	$850,000

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (USD $)	6 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted Average Exercise Price per share , Outstanding	$0.10
Stock Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding	3,400,556
Number of Shares, Granted	3,042,480
Number of Shares, Exercised	42,499
Number of Shares, Canceled	0
Number of Shares, Outstanding	6,400,537
Weighted Average Exercise Price per share, Granted	$4.58
Weighted Average Exercise Price per share, Exercised	$0
Weighted Average Exercise Price per share, Expired	$0
Weighted Average Exercise Price per share, Canceled	$0
Weighted Average Exercise Price per share , Outstanding	$4.66
Weighted Average Remaining Contractual Term, (year) Granted	'2 years 11 months 26 days
Weighted Average Remaining Contractual Term, (year) Exercised	'0 years
Weighted Average Remaining Contractual Term, (year) Expired	'0 years
Weighted Average Remaining Contractual Term, (year) Canceled	'0 years
Weighted Average Remaining Contractual Term, (year) Outstanding	'2 years 6 months 11 days
Aggregate Intrinsic Value, Outstanding	$0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Canceled	0
Aggregate Intrinsic Value, Outstanding	$3,928,098

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details Textual) (USD $)	12 Months Ended						1 Months Ended
	Jun. 30, 2009	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Sep. 30, 2005	Sep. 30, 2005	Sep. 30, 2005	16-May-07
		June 30, 2014 [Member]	June 30, 2015 [Member]	June 30, 2016 [Member]	June 30, 2017 [Member]	June 30, 2018 [Member]	Chief Executive Officer [Member]	President [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	'	'	'	500,000	1,000,000	500,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	'	'	'	'	'	'	250,000	333,333	250,000	375,000
Allocated Share-based Compensation Expense	$7,044	'	'	'	'	'	'	'	'	'
Warrants Exercisable	'	3,190,557	65,714	68,571	68,571	3,007,124	'	'	'	'
Warrants Expiration Date	'	30-Jun-14	30-Jun-15	30-Jun-16	30-Jun-17	30-Jun-18	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	6 Months Ended				1 Months Ended	6 Months Ended	11 Months Ended
	Feb. 28, 2011	Dec. 31, 2013	Dec. 31, 2012	Feb. 11, 2013	Feb. 11, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 17, 2013	Feb. 11, 2013
	acre				Thera Cour Pharma, Inc [Member]	Inno Haven [Member]	Inno Haven [Member]	Inno Haven [Member]	Inno Haven [Member]	Inno Haven [Member]
										acre
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Space For Office and Laboratory	7,000	'	'	'	'	'	'	'	'	'
Monthly Base Rent	$8,695	'	'	'	'	'	'	'	'	'
Lease Expiration Date	28-Feb-11	'	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense, Net	'	52,170	52,170	'	'	'	0	0	'	'
Cash Collateral for Borrowed Securities	'	'	'	1,000,000	1,000,000	'	'	'	2,000,000	2,000,000
Securities Received as Collateral	'	'	'	'	'	'	'	'	1,000,000	'
Securities Owned and Pledged as Collateral, Description	'	'	'	'	'	'The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares.	'	'	'	'
Fixtures And Improvements	'	1,100,000	'	'	'	'	'	'	'	'
Area of Land	'	'	'	'	'	'	'	'	'	18,000
Debt Instrument, Annual Principal Payment	'	'	'	$2,000,000	'	'	'	'	'	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

Dec. 31, 2013

Nov. 30, 2013

Aug. 31, 2013

Dec. 31, 2013

Sep. 25, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 02, 2013

Feb. 06, 2014

Jan. 21, 2014

Jan. 22, 2014

Jan. 24, 2014

Dec. 31, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

'

'

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

'

17,143

21,000

35,357

'

'

'

'

25,000

'

75,000

'

'

Purchase Price Per Share

'

'

'

$5.25

'

'

'

'

'

$5.25

'

'

'

Warrants Exercisable

'

'

'

'

'

'

'

'

25,000

'

75,000

'

'

Warrants Exercise Price

$3.50

'

'

$5.25

'

'

'

'

$5.25

$6.05

$5.25

'

'

Warrants Expire Period

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Proceeds From Issuance Initial Public Offering

'

'

'

$10,308,996

'

'

'

'

$131,250

'

$393,750

$20,030,246.25

$20,030,246.25

Placement Agents and Attorneys Fees

'

'

'

$618,540

'

'

'

'

'

'

'

$1,200,000

'

Purchase And Sale Of Common Stock

'

'

'

'

'

'

'

'

'

'

'

3,815,285

'

Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

2,479,935

'

Purchase Price Unit Description

'

'

'

'

'

'

'

'

'

'The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Registrants stock price on Friday, January 17, 2014.

'

'

'